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This supplement contains the conference abstracts accepted at the
MEMTAB2020 virtual symposium, hosted from Leuven, Belgium, fo-
cussing on Methods for Evaluation of Medical prediction Models,
Tests And Biomarkers.
The MEMTAB2020 symposium was hosted by Professor Ben Van Cal-
ster, Professor Ann Van den Bruel, Professor Jan Verbakel and the
University of Leuven's EPI-Centre, part of the Department of Public
Health and Primary Care.
The international MEMTAB symposium attracts researchers, health-
care workers, policy makers and manufacturers actively involved in
the development, evaluation or regulation of tests, (bio) markers,
models, tools, apps, devices or any other modality used for the pur-
pose of diagnosis, prognosis, risk stratification or (disease or therapy)
monitoring.
Rapid technological progress coupled with the significant methodo-
logical complexities involved in developing, evaluating and imple-
menting tests, markers, models or devices create formidable
challenges. Yet these challenges are matched by unique opportun-
ities, while the wide array of involved subdisciplines create an excit-
ing milieu for the generation of new ideas and directions. The
symposium aims to provide a forum for disseminating knowledge at
the forefront of current research, and for stimulating dialogue that
will propel future thought and endeavours to tackle the methodo-
logical and practical complexities facing the medical diagnostic,
prognostic and monitoring field today. The virtual MEMTAB2020
event was specifically aimed at bringing together researchers from
the diverse reaches of test evaluation, from in vitro test developers,
industry and regulatory representatives, through methodologists,
guideline developers and practising clinicians, in the hope of improv-
ing current understanding through knowledge exchange, and for-
ging our diverse experiences and perspectives to delineate the
future direction of diagnostic test research. In this respect, it is the
only conference in the world that provides a platform dedicated to
the investigation of medical tests, markers, models and other devices
used for diagnosis prognosis and monitoring.
This year’s symposium focussed on the following conference themes:
 How to develop and apply prediction models and diagnostic tests
 High-dimensional data and genetic prediction
 Machine learning for evaluation of diagnostic tests, markers
and prediction models
 Impact studies for diagnostic tests, markers and prediction
models (including low resource settings)
 Systematic review and meta-analysis (including individual par-
ticipant data)
 Big data, electronic health records, dynamic prediction
 How to quantify overdiagnosis
With over 135 delegates and 88 accepted abstracts, we believe we
were able to offer a very strong programme.
It was our great pleasure to host this year’s symposium and are look-
ing forward to meeting you again at the next MEMTAB symposium!
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Using Group Data for Individual Patients: The Predictive
Approaches to Treatment Effect Heterogeneity (PATH) Statement
David M Kent1, David van Klaveren1,2, Jessica K. Paulus1 and Ewout
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University Medical Center, Rotterdam, The Netherlands; 3Department of
Biomedical Data Sciences, Leiden University Medical Center, Leiden, The
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Background: Evidence-based medicine (EBM) relies on forecasting
for an individual patient using the frequency of outcomes in
groups of similar patients (i.e., a reference class) under alternative
treatments. Despite a widespread belief that individuals respond
differently to the same treatment, EBM has traditionally stressed
the reference class of the whole trial population, in part because
conventional (one-variable-at-a-time) subgroup analysis have well-
known limitations.
We aimed to provide guidance for “predictive” approaches to
heterogeneous treatment effects (HTE), which can provide
patient-centered estimates of outcome risks under treatment al-
ternatives, taking into account multiple relevant patient attributes
simultaneously.
Methods: 1) a systematic literature review; 2) simulations to charac-
terizing potential problems with predictive HTE analysis; and 3) a de-
liberative process engaging a technical expert panel to develop
guidance.
Results: We found various limitations of conventional subgroup ana-
lysis in contrast to various advantages of predictive approaches. The
latter span two broad classes: 1) Risk modeling, where patient sub-
groups are formed according to their risk of an outcome (usually the
primary study outcome), exploiting the mathematical dependency of
treatment effects on the control event rate; and 2) Effect modeling,
where patients are disaggregated by a model developed directly
from randomized trial data to predict treatment effects (i.e., contrast-
ing outcome risks under two treatment conditions). Unlike risk mod-
eling, effect modeling is “unblinded” to treatment assignment,
allowing the inclusion of treatment-by-covariate interaction terms.
We review strengths and limitations of these approaches and
summarize recommendations in the PATH Statement.
Conclusions: While positive RCT results provide strong evidence that
an intervention works for at least some patients, clinicians need to
understand how a patient’s multiple characteristics combine to influ-
ence their potential treatment benefit. Revision and refinement of
the PATH guidance supporting that goal is anticipated as experience
with these novel methods grows.
Keywords: PATH statement, prediction, heterogeneity of treatment
effect, personalized medicine
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Ewout W. Steyerberg1,2, David M Kent3, David van Klaveren1,3
1Department of Biomedical Data Sciences, Leiden University Medical
Center, Leiden, The Netherlands; 2 Department of Public Health, Erasmus
University Medical Center, Rotterdam, The Netherlands; 3 Predictive
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Boston, MA, USA
Correspondence: Ewout W. Steyerberg
Diagnostic and Prognostic Research 2021, 5(Suppl 1):2.
Background: Heterogeneity of treatment effect refers to the nonran-
dom variation in the magnitude of the absolute treatment effect
('benefit') across levels of covariates. For randomized controlled trials
(RCTs), the PATH (Predictive Approaches to Treatment effect Hetero-
geneity) Statement suggests 2 categories of predictive HTE ap-
proaches: “risk modeling” approaches, which combine a multivariable
model with a constant relative effect of treatment, and “effect mod-
eling” approaches, which includes interactions between treatment
and baseline covariates[1].
We aimed to assess practical challenges in deriving estimates of ab-
solute benefit based on risk modeling.
Methods & Results: We re-analyzed data from 30,510 patients with
an acute myocardial infarction, as enrolled in the GUSTO-I trial[2].
The average mortality was 6.3% with tPA and 7.3% with strepto-
kinase, or an average benefit of 1.0% (p<.001). A multivariable lo-
gistic regression model included 6 predictors of 30-day mortality,
which occurred in 2128 patients. The model provided a linear
predictor (or risk score) that discriminated well between low risk
and high risk patients, with an area under the ROC curve of 0.82.
The benefit of tPA over streptokinase treatment increased from
0.2% to 2.4% for the lowest to the highest risk quarter (Figure 1).
Proportionality of the treatment effect across predictors was not
rejected in tests of interaction (overall test: p=0.30). Continuous
benefit was estimated by subtracting estimated risk under either
treatment with a spline transformation of the linear predictor
(Figure 1). Sensitivity analyses showed similar results for different
specifications of the risk model or the continuous benefit model-
ing. Exploratory one at a time subgroup analyses showed consist-
ent relative effects of treatment.
Conclusions: Risk modeling should become part of the primary ana-
lysis of RCTs. One at a time subgroup analyses should be abandoned
as secondary to indicate any heterogeneity of treatment effect.
Keywords: Heterogeneity of treatment effect, regression model,
spline functions
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Fig. 1 (abstract 2). benefit of treatment by tPA compared to
streptokinase in the GUSTO-I trial
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Application of the PATH Statement: Predicting Treatment Benefit
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Background: The Syntax Score II (SSII) was proposed to predict
treatment benefit, i.e. the DIFFERENCE in 4-year mortality when
treating complex Coronary Artery Disease patients with heart by-
pass surgery rather than coronary stenting. Between 4 and 10
years post-procedure, SSII has shown good predictive perform-
ance for mortality, but not for the treatment benefit of surgery
versus stenting.
We aimed to develop a new SSII (SSII-2020) for predicting the treat-
ment benefit of surgery versus stenting over a 10-year horizon.
Methods: Following the recently published PATH statement, we first
used Cox regression in the SYNTAX trial data (n=1,800) to develop a
clinical prognostic index (PI) for mortality over a 10-year horizon,
blinded to treatment assignment. Second, we fitted a Cox model
which included the treatment, the PI and 2 pre-specified effect-
modifiers based on prior evidence: type of disease (Left Main Disease
[LMD] or 3-Vessel Disease [3VD]), and anatomical disease complexity
(SYNTAX Score [SS]). In a cross-validation, we assessed the ability of
SSII-2020 to predict the absolute mortality difference between sur-
gery and stenting.
Results: The PI consisted of 7 clinical predictors of mortality. SSII-
2020 included the PI, treatment and 2 significant treatment interac-
tions: surgery was on average beneficial for 3VD patients (HR 0.66;
95%CI 0.52-0.84), but not for LMD patients (HR 1.17; 95%CI 0.77-1.36;
p-for-interaction 0.02), and the disease complexity only influenced
mortality risk when patients were treated with stenting (HR per 10 SS
points 1.17; 95%CI 1.06-1.30; p-for-interaction 0.05). In both treat-
ment arms, SSII-2020 discriminated well (c-index 0.73) and was well
calibrated for mortality risk. In contrast with SSII, SSII-2020 was well
calibrated for treatment benefit both at 5 and 10 years post-
procedure (Figure 1).
Conclusions: The newly developed SSII-2020 is able to predict the
treatment benefit of heart bypass surgery versus coronary stenting
over a 10-year horizon. External validation will be undertaken.
Keywords: PATH statement, prediction, heterogeneity of treatment ef-
fect, personalized medicine
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Individual participant data meta-analysis to examine treatment-covariate
interactions: statistical recommendations for conduct and planning
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Background: Personalised healthcare often requires the use of treatment-
covariate interactions, which refers to when a treatment effect (e.g. mea-
sured as a mean difference, odds ratio, hazard ratio) changes across values
of a participant-level covariate (e.g. age, biomarker). Single randomised trials
do not usually have sufficient power to detect genuine treatment-covariate
interactions, which motivates the sharing of individual participant data (IPD)
from multiple trials for meta-analysis. However, IPD meta-analyses are time
consuming and statistically challenging
We aimed to provide statistical recommendations for conducting
and planning an IPD meta-analysis of randomised trials to examine
treatment-covariate interactions.
Methods: Drawing on our collective experience, we identify five key
lessons to improve statistical analysis, and two key recommendations
to improve planning IPD meta-analysis projects. Real IPD meta-
analysis examples are used to substantiate the issues.
Results: For conduct, we recommend: (i) interactions should be estimated
directly, and not by calculating differences in meta-analysis results for sub-
groups; (ii) interaction estimates should be based solely on within-study in-
formation; (iii) continuous covariates and outcomes should be analysed on
their continuous scale; (iv) non-linear relationships should be examined for
continuous covariates, using a multivariate meta-analysis; and (v) translation
into clinical practice requires individualised treatment effect prediction. For
planning, the decision to initiate an IPD meta-analysis should (a) not be
based on between-study heterogeneity in the overall treatment effect; and
(b) consider the potential power of an IPD meta-analysis conditional on
characteristics of studies promising their IPD.
Conclusions: We hope our recommendations improve the planning and con-
duct of IPD meta-analyses to examine treatment-covariate interactions, to help
flag when the approach is worthwhile and to ensure more robust results.[1]
Keywords: IPD meta-analysis, effect modifier, treatment-covariate
interaction, subgroup
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Fig. 1 (abstract 3). Calibration plots for benefit of treatment with
surgery versus stenting at 5 years (left panel) and 10 years (right
panel)
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Background: It is useful for developers of diagnostic technologies to
know how accurate a test predicting response to a treatment would
need to be in order for a “test and treat” strategy to produce super-
ior clinical outcomes to a ‘treat all’ strategy.
This study explored the derivation of a set of sensitivity and specifi-
city values that define the threshold for clinical superiority for a test
and treat strategy.
Methods: Taking the scenario of a test that predicts response to
treatment A with a given sensitivity and specificity but does not pre-
dict the response to an alternative treatment (B), we developed a
mathematical model that determined the threshold sensitivity and
specificity required for a strategy of test and treat with “A” if positive
or “B” if negative to outperform a treat-all strategy with either treat-
ment A or B.
Results: We demonstrated that an estimate of odds ratio of response
rate between treatments is sufficient to determine a set of threshold
sensitivities and specificities for clinical superiority of the test and
treat strategy. However, if the absolute probability of response is
known for one of the treatments, the net-clinical benefit of the test
can be estimated as a function of sensitivity and specificity. Using a
hypothetical test of response to hormone treatment compared to
chemotherapy in ovarian cancer, we demonstrate in a Shiny App the
“Test and Treat Superiority Plot”, which illustrates the threshold per-
formance necessary for a test of treatment response to outperform a
treat all strategy given only the odds ratio between two treatments.
Conclusions: This model and plot can be used to distinguish promis-
ing candidate diagnostics from those unlikely to have clinical value.
The plot also indicates how the relative importance of sensitivity and
specificity varies as a function of the relative treatment effect.
Keywords: Diagnostic tests, sensitivity and specificity, test development
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Background: In diagnostic accuracy studies, sensitivity and specificity
are recommended as co-primary endpoints. For the sample size cal-
culation, assumptions about the expected sensitivity and specificity
of the index test as well as the minimal acceptable diagnostic accur-
acy or the expected diagnostic accuracy of the comparator test have
to be made. However, the assumptions from previous studies are
often unsure.[1] As an example for the talk we chose the study from
Yan et al., where the estimated sensitivity was 75.8%, whereas the
authors expected 91%.[2]
Methods: Because of the uncertainty, it is essential to develop
methods for a sample size re-estimation in diagnostic accuracy trials.
While such adaptive designs are standard in interventional trials, in
diagnostic trials they are uncommon.[3] Known approaches from
interventional trials cannot be applied to diagnostic accuracy studies
or have to be modified; especially because the specific feature of
diagnostic accuracy trials are the two co-primary endpoints sensitiv-
ity and specificity.
Results: In this talk we propose an approach for an unblinded sam-
ple size re-estimation in diagnostic accuracy studies. We can show
that with the adaptive design the type-one error is maintained and
the desired power is achieved. Furthermore, the results of the ex-
ample study are presented.
Conclusion: Using unblinded sample size re-estimation, diagnostic
accuracy studies can be made more efficient.
Keywords: Diagnostic accuracy, adaptive design, unblinded interim
analysis
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Background: Systematic reviews include primary studies that differ
in sample sizes, with larger studies contributing more to the meta-
analysis. At present, study size is not considered in Risk of Bias
evaluations.
We aimed to develop an alternative way to present the contribution
of individual studies to the total body of evidence on diagnostic ac-
curacy, in terms of risk of bias and concerns about applicability, one
that takes the effective sample size into account.
Methods: We used the results of a systematic review of diagnostic
accuracy studies of the Enhanced Liver Fibrosis (ELF) test for diagnos-
ing liver fibrosis among non-alcoholic fatty liver disease patients. We
assessed the 11 studies identified from our systematic search of five
databases with the QUADAS-2 (Quality Assessment of Diagnostic Ac-
curacy Studies) tool. We first used number of studies to show the
proportion of studies at low, unclear and high risk of bias. We then
developed an alternative version of the graph, which relies on the
proportion of the total sample size of studies at different levels of
risk of bias.
Results: The risk of bias levels for each domain of the QUADAS-2
checklist changed after replacing the number of studies with the
relative sample sizes of the individual studies. For instance, the risk
of bias was high in the patient selection domain in 45% of the stud-
ies, and low and unclear in 27% of studies (Figure 1A). The alterna-
tive graph using the sample sizes showed 25%, 41% and 34% of
included population with high risk, unclear and low risk of bias, re-
spectively (Figure 1B).
Conclusion: A fair representation of the risk-of-bias and concerns
about applicability in the available body of evidence from diagnostic
accuracy studies should be based on the total sample size, not on
the number of studies
Keywords: Meta-analysis, accuracy studies, risk of bias assessment
Fig. 1 (abstract 7). Risk of bias assessment results based on (A)
proportion of included studies in the systematic review. (B)
proportion of included patients in the systematic review
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Background: Three previous individual participant data meta-
analyses (IPDMAs) found that, compared to the semi-structured
Structured Clinical Interview for DSM (SCID), the Composite Inter-
national Diagnostic Interview (CIDI) and Mini International Neuro-
psychiatric Interview (MINI) tended to misclassify major depression.
We aimed to synthesize results from the three studies to compare
the performance of the most commonly used diagnostic interviews
for major depression classification: the SCID, CIDI, and MINI; and to
determine if (1) probability of major depression classification based
on the CIDI and MINI differs from probability based on SCID and (2)
if differences are associated with depressive symptom levels.
Methods: We updated the Patient Health Questionnaire-9 IPDMA
database, and standardised screening tool scores in all three data-
bases. We re-analysed by fitting binomial generalized linear mixed
models to compare odds of major depression classification across in-
terviews, controlling for screening tool scores and participant charac-
teristics, with and without an interaction term between interview
and screening score. We synthesised results from these IPDMAs by
estimating pooled adjusted odds ratios (aORs) for each interview and
for interactions of each interview with screening scores using ran-
dom effects meta-analysis.
Results: In total, 69,405 participants (7,574 [11%] with major depres-
sion) from 212 studies were included. The MINI (74 studies, 25,749
participants, 11% major depression) classified major depression more
often than the SCID (108 studies, 21,953 participants, 14% major de-
pression; aOR [95% CI] = 1.45 [1.11-1.92]). As screening scores in-
creased, odds of major depression classification increased less for the
CIDI (30 studies, 21,703 participants, 7% major depression) than the
SCID (interaction aOR [95% CI] = 0.64 [0.52-0.80]).
Conclusions: Compared to the SCID, the MINI classifies major depres-
sion more often and the CIDI is less responsive to increases in symp-
tom levels, regardless of measure of depressive symptom severity.
Findings from research studies using MINI or CIDI should be cau-
tiously interpreted.
Keywords: Depressive disorders, diagnostic interviews, individual par-
ticipant data meta-analysis, major depression
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Background: Although a large number of resources have been
invested in biomarker (BM) discovery, for both prognostic and diag-
nostic purposes, very few of those BMs have been clinically adopted.
In an attempt to bridge the gap between BM discovery and clinical
use, our previous study has developed and retrospectively validated
a checklist comprised of 125 characteristics associated with cancer
BM clinical implementation. Despite validation, complexity in imple-
menting the full checklist might present a barrier. Therefore, this
study aims to generate a user-friendly and concise consensus state-
ment with literature-reported attributes associated with successful
BM implementation.
Methods: A checklist of BM attributes was created using Medline
and Embase databases according to PRISMA guidelines. A qualitative
approach was applied to validate the list utilising semi-structured in-
terviews (n=32). Thematic analysis was conducted until thematic sat-
uration was achieved. Upon completion of literature review and
interviews, a 3-phase online Delphi-Survey was designed aiming to
develop a consensus document. The participants involved were
grouped based on their expertise: clinicians, academics, patient and
industry representatives.
Results: Previously identified 125 attributes retrieved from literature
and reporting guidelines were included in the checklist. Upon the-
matic analysis of the interviews, characteristics listed in the checklist
were validated. Most commonly occurring theme focused on clinical
utility. Interestingly, different groups focused on differential themes
emphasising the importance of participants’ diverse background. In
specific, clinician and laboratory personnel commonly occurring
themes fell under clinical utility. Moreover, patient representatives
and industry personnel recurrent themes focused on clinical and ana-
lytical validity, respectively.
Conclusions: This study generated a validated checklist with
literature-reported attributes linked with successful BM implementa-
tion. Upon completion of the Delphi-survey, a consensus statement
will be generated which could be used to i) detect BMs with the
highest potential of being clinically implemented and ii) shape how
BM studies are designed and performed.
Keywords: Biomarkers, clinical implementation, checklist, Delphi sur-
vey, qualitative research
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Background: A Target Product Profile (TPP) is a strategic document
which describes the necessary characteristics of an innovative prod-
uct to address an unmet clinical need. TPPs present valuable infor-
mation for designing ‘fit for purpose’ tests to manufacturers. To our
knowledge, there is no formal guidance as to best practice methods
for developing a TPP specific to medical tests.
We aimed to review and summarise the methods currently used to
develop TPPs for medical tests and identify the test characteristics
commonly reported.
Methods: We conducted a methodology systematic review of TPPs for
medical tests. Database and website searches were carried out in Novem-
ber 2018. TPPs written in English for any medical test were included. Test
characteristics were clustered into commonly recognized themes.
Results: Forty-four studies were identified, all of which focused on
diagnostic tests for infectious diseases. Three core decision-making
phases for developing TPPs were identified: scoping, drafting and
consensus-building. Consultations with experts and the literature
mostly informed the scoping and drafting of TPPs. All TPPs provided
information on unmet clinical need and desirable test analytical per-
formance, and the majority specified clinical validity characteristics.
Few TPPs described specifications for clinical utility, and none in-
cluded cost-effectiveness.
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Conclusions: Based on our descriptive summary of the methods im-
plemented, we have identified a commonly used framework that
could be beneficial for anyone interested in drafting a TPP for a med-
ical test. We also highlighted some key weaknesses, including the
quality of the information sources underpinning TPPs and failure to
consider test characteristics relating to clinical utility and cost-
effectiveness. This review provides some recommendations for fur-
ther methodological research on the development of TPPs for med-
ical test. This work would also help to inform the development of a
formal guideline on how to draft TPPs for medical tests.
Keywords: Medical test, target product profile, TPP, quality by design,
diagnostic, test characteristic
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Background: The assessment of agreement in method comparison
and observer variability analysis on quantitative measurements is
often done with Bland-Altman Limits of Agreement (BA LoA) for
which the paired differences are implicitly assumed to follow a Nor-
mal distribution. Whenever this assumption does not hold, the re-
spective 2.5% and 97.5% percentiles are often assessed by simple
quantile estimation.
Sample, subsampling, and Kernel quantile estimators as well as other
methods for quantile estimation have been proposed in the literature
and were compared in this simulation study.
Methods: Given sample sizes between 30 and 150 and different
distributions of the paired differences (Normal; Normal with 1%,
2%, and 5% outliers; Exponential; Lognormal), the performance of
14 estimators in generating prediction intervals for one newly
generated observation was evaluated by their respective coverage
probability.
Results: For n=30, the most simple sample quantile estimator (smal-
lest and largest observation as estimates for the 2.5% and 97.5% per-
centiles) outperformed all other estimators. For sample sizes of n=50,
80, 100, and 150, only one other sample quantile estimator (a
weighted average of two order statistics) complied with the nominal
95% level in all distributional scenarios. The Harrell-Davis subsamp-
ling estimator and estimators of the Sfakianakis-Verginis type
achieved at least 95% coverage for all investigated distributions for
sample sizes of at least n=80 apart from the Exponential distribution
(at least 94%).
Conclusions: Simple sample quantile estimators based on one and
two order statistics can be used for deriving nonparametric Limits of
Agreement. For sample sizes exceeding 80 observations, more ad-
vanced quantile estimators of the Harrell-Davis and Sfakianakis-
Verginis types that make use of all observed differences are equally
applicable, but may be considered intuitively more appealing than
simple sample quantile estimators that are based on only two obser-
vations per quantile (Figure 1).
Keywords: Agreement, Bland-Altman plot, coverage, prediction,
quantile estimation, repeatability, reproducibility
Contributed session on prediction
models
Session chair: Laure Wynants
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Background: Comparative diagnostic test accuracy studies assess the
accuracy of multiple tests in the same study and compare their ac-
curacy. While these studies have the potential to yield reliable evi-
dence regarding comparative accuracy, shortcomings in the design,
conduct and analysis may bias their results. The currently recom-
mended quality assessment tool for diagnostic accuracy studies,
QUADAS-2, is not designed for the assessment of test comparisons.
We developed QUADAS-C as an extension to QUADAS-2 to assess
the risk of bias in comparative diagnostic test accuracy studies.
Methods: Through a four-round Delphi study involving 24 international
experts in test evaluation and a face-to-face consensus meeting, we de-
veloped a draft version of QUADAS-C which will undergo piloting in on-
going systematic reviews of comparative diagnostic test accuracy.
Results: QUADAS-C retains the same four-domain structure of
QUADAS-2 (patient selection, index test, reference standard, flow and
timing) and is comprised of additional questions to each QUADAS-2
Fig. 1 (abstract 11). A sample quantile estimator (weighted average
of two order statistics; solid), Harrell-Davis subsampling estimator
(short dashes and dots), and an estimator of Sfakianakis-Verginis type
(long dashes) contrasted with classical BA LoA (shaded area); n=129.
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domain. A risk of bias judgement for comparative accuracy requires
a risk of bias judgement for each test (QUADAS-2), and additional cri-
teria specific for test comparisons. Examples of such additional cri-
teria include whether patients either received all index tests or were
randomized to index tests, and whether index tests were interpreted
blinded to other index tests.
Conclusions: QUADAS-C will be useful for systematic reviews of diag-
nostic test accuracy addressing comparative accuracy questions. Fur-
thermore, researchers may use this tool to identify and avoid risk of
bias when designing a comparative diagnostic test accuracy study.
Currently a draft version of QUADAS-C is being piloted and the tool
will be finalized by the time of the conference.
Keywords: Diagnostic accuracy, bias, test comparison, methodology,
systematic review
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Background: Once a clinical prediction model has been devel-
oped its predictive performance should be examined in new
data, independent to that used for model development. This
process is known as external validation. Many current external
validation studies suffer from small sample sizes and, subse-
quently, imprecise estimates of a model’s predictive performance.
To address this, in our talk we propose methods to determine the
minimum sample size needed for external validation of a clinical pre-
diction model with a continuous outcome.
Methods: Four criteria are proposed, that target precise estimates
of (i) R2 (the proportion of variance explained), (ii) calibration-in-
the-large (agreement between predicted and observed outcome
values on average), (iii) calibration slope (agreement between
predicted and observed values across the range of predicted
values), and (iv) the variance of observed outcome values.
Closed-form sample size solutions are derived for each criterion,
which require the user to specify anticipated values of the
model’s performance (in particular R2) and the outcome variance.
Results: The sample size formulae require the user to specify their
desired precision for each performance estimate, whilst also mak-
ing assumptions about the anticipated distribution of predicted
values and the expected model performance in the validation
study. For the latter, a sensible starting point is to base values
on those reported in the model development study, assuming
the target population is similar. The largest sample size required
to meet all four criteria is the recommended minimum sample
size needed in the external validation dataset. We illustrate the
proposed methods on a case-study predicting fat-free mass in
children, with the criteria suggesting a sample size of at least
234 participants are needed.
Conclusion: We recommend that researchers consider the minimum
sample size required to precisely estimate key predictive perform-
ance measures, before commencing external validation of a predic-
tion model for a continuous outcome.
Keywords: Sample size, external validation, prediction model, con-
tinuous outcome
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Background: Clinical prediction models (CPMs) are of great interest
to Oncology clinicians, who can use past and current patient charac-
teristics to inform current and future health status. However, system-
atic reviews show that CPMs are often developed and validated
using inappropriate methodology and are poorly reported. Applica-
tion of Machine Learning (ML) methods to develop CPMs has risen
considerably and it is often portrayed to offer many advantages (over
traditional statistical methods), especially when using ‘big’, non-linear
and high-dimensional data. However, poor methodology and report-
ing continue to be barriers to their clinical use. To improve usability
of ML-CPMs, it is important to evaluate their methodological quality
and adherence to reporting guidelines for prediction modelling.
We aimed to evaluate methodological conduct and reporting of
author-defined ML-CPM studies within Oncology.
Methods: We conducted a systematic review of Oncology ML-CPMs
published in 2019 using MEDLINE and Embase. We excluded studies
using imaging or lab-based data. We extracted data on study design,
outcome, sample size, ML methodology, and items for risk of bias[1].
The primary outcome was adherence to prediction modelling report-
ing guidelines[2].
Results: We identified 2922 publications and excluded 2843 based
on the eligibility criteria; extracting data from 79 publications. Prelim-
inary results show poor reporting and methodological conduct. Stud-
ies used inefficient validation methods (e.g., split-sample) and did
not adequately address missing data. Sample size was not reported
for most studies, and discrimination was emphasised over calibration.
Studies were at increased risk of overfitting, leading to optimistic
performance measures for their models.
Conclusions: Reporting and methodological conduct of Oncology
ML-CPMs needs to be improved. Caution is needed when interpret-
ing ML-CPMs as performance may be over-optimistic.
Keywords: Machine learning, prediction modelling, reporting
References
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Background: When developing models for prediction, neither the pa-
rameters of the model, nor the output predictions, have any causal
interpretations. For pure prediction this is perfectly acceptable.
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However, prediction models are commonly interpreted in a causal
manner - for example by altering inputs to the model to demon-
strate hypothetical impact of an intervention. This can lead to biased
causal effects being inferred, and thus misinformed decision making.
We aimed to collect examples of use of prediction models in a causal
manner in practice, and to identify and interpret literature that pro-
vides methods for enriching prediction models with causal
interpretations.
Methods: We systematically reviewed literature to identify methods
for prediction models with causal interpretations, by adapting a
scoping review framework, and considering the interaction of predic-
tion modelling keywords, and causal inference keywords. We in-
cluded papers where methods are developed or applied that
undertake prediction enriched with causal inference methods; specif-
ically allowing for some assessment of the causal impact of an inter-
vention on predicted risk.
Results: There were two broad categories of approach identified: 1)
enriching prediction models with externally estimated causal effects,
such as from meta-analyses of clinical trials; and 2) estimating both a
prediction model, and causal effects, from observational data. The
latter category included methods such as marginal structural models
and g-estimation, embedded within both statistical and machine
learning frameworks.
Conclusions: There is a need for prediction models that allow for
'counterfactual prediction': i.e. estimating risk of outcomes under dif-
ferent hypothetical interventions, to support decision making.
Methods exist but require development, particularly when triangulat-
ing data from different sources (e.g. observational data and rando-
mised controlled trials). Techniques are also required to validate such
models.
Keywords: Causal, counterfactual, prediction, model
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Background: When evaluating the performance of risk prediction
models, calibration is often underappreciated. There is little research
on calibration for discrete ordinal outcomes.
We aimed to compare calibration measures for risk models that pre-
dict a discrete ordinal outcome (typically 3 to 6 categories), investi-
gate the impact of assuming proportional odds on risk estimates and
calibration, and study the impact of assuming proportional odds.
Methods: We studied multinomial logistic, cumulative logit, adjacent
category logit, continuation ratio logit, and stereotype logistic
models. To assess calibration, we investigated calibration intercepts
and slopes for every outcome level, for every dichotomised version
of the outcome, and for every linear predictor (i.e. algorithm-specific
calibration). Finally, we used the estimated calibration index as a
single-number metric, and constructed calibration plots. We used
large sample simulations to study the behaviour of the logistic
models in terms of risk estimates, and small sample simulations to
study overfitting. As a case study, we used data from 4,888 symp-
tomatic patients to predict the degree of coronary artery disease (five
levels, from no disease to three-vessel disease).
Results: Models assuming proportional odds easily resulted in incor-
rect risk estimates. Calibration slopes for specific outcome levels or
for dichotomised outcomes often deviated from unity, even on the
development data. Non-proportional odds models, however, suffered
more from overfitting, because these models require more parame-
ters. Algorithm-specific calibration for proportional odds models as-
sumes that this assumption holds, and therefore did not fully
evaluate calibration.
Conclusions: Deviations from the proportional odds assumption can
result in poor risk estimates and calibration. Therefore, non-
proportional odds models are generally recommended for risk pre-
diction, although larger sample sizes are needed.
Keywords: Prediction, calibration, ordinal outcome, proportional
odds
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Background: Reporting of clinical prediction models has been shown
to be poor with information on the intercept often missing. To allow
application of a model for individualized risk prediction, information
on the intercept is essential.
We aimed to evaluate possible methods to estimate an unreported
intercept of a logistic regression model.
Methods: Using existing data, we developed a logistic regression
model with 6 predictors to predict the risk of operative delivery in
pregnant women. We considered 4 scenarios which did not report
the intercept, but in which different information was available: i) web
calculator, ii) nomogram, iii) coefficients/odds ratios, and iv) scoring
table (i.e., three simplified categories and corresponding predicted
probabilities). In scenario i) and ii), the coefficient for each predictor
was estimated by assessment of the change in predicted probabil-
ities that occurred with the change in the particular predictor. Then,
the intercept was estimated by calculating the differences between
the predicted probability and the estimated predictor coefficients. In
scenario iii), the intercept was estimated based on the assumption
that the mean risk estimated by the model would be close to the ob-
served incidence of the outcome in a patient who had the mean
value for each predictor. In scenario iv), the intercept was estimated
by the association between score categories and corresponding pre-
dicted probabilities.
Results: Among 5667 laboring women, 1590 (28.1%) had an operative de-
livery. While the true value of the intercept was -9.563, the estimated inter-
cept in each scenario was -9.552, -9.580, -9.308, and -8.940, respectively.
Conclusion: In scenarios i) and ii) where detailed information of pre-
dicted probability is available, the unreported intercept can be accur-
ately estimated. On the other hand, the estimation of the intercept
could be unstable when only coefficients/odds ratios or simple scor-
ing and corresponding predicted probabilities are reported.
Keywords: Intercept, prediction model, logistic regression
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Background: AI based smartphone diagnostic apps can empower app
users to make risk assessments and diagnoses. Apps for assessing suspi-
cious moles for skin cancer are being implemented in health systems in
the UK and elsewhere.
As a case study of AI, we examined the validity and findings of studies of AI
smartphone apps to assess suspicious lesions for skin cancer, and assessed
regulatory and NHS implementation processes.
Methods: We searched eight major databases and registers, including ac-
curacy studies of any design. Reference standards included histological
diagnosis and follow-up, or expert assessment. QUADAS-2 assessments
summarised weaknesses in the evidence. Consequently we investigated
how evidence is used with the MHRA and the NHS.
Results: Nine small studies evaluating six smartphone apps were
found, two further studies have been provided since. QUADAS-2 as-
sessments showed studies at high risk of bias with selective recruit-
ment, unevaluable images, and differential verification. Applicability
concerns included recruitment in secondary care clinics; clinicians
performing lesion selection and image acquisition, and commercial
confidentiality, name changes, and no version identifiers preventing
app identification. Sensitivity estimates improved over time, but spe-
cificity remained below 80%. Two apps have CE marks as Class 1 de-
vices. The Intended Use Statements state apps should not be used
instead of medical assessments. NHS marketing material did not re-
port specificity values, implied favorable comparisons with health
professionals, and was contrary to the Intended Use statement. The
NHS AI implementation process does not require a formal independ-
ent assessment of evidence.
Conclusions: Evidence does not support use of smartphone apps to detect
melanoma. Current marketing of one app is contrary to its authorisation,
and there is serious risk of harm to the public as a result. We have reported
our findings to the NHS and the regulators and will update on what hap-
pened next.
Keywords: AI, apps, evidence, regulation
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Background: The TRIPOD (Transparent Reporting of a multivariable
prediction model for Individual Prognosis Or Diagnosis) Statement is
a widely acknowledged guideline for the reporting of studies devel-
oping, validating, or updating a prediction model. With increasing
availability of large datasets (or “big data”) from electronic health
records and from individual participant data (IPD) meta-analysis,
authors face novel opportunities and challenges for conducting
and reporting their prediction model research. In particular, when
prediction model development and validation studies include par-
ticipants from multiple clusters such as multiple centers or studies,
prediction models may generalize better across multiple centers,
settings and populations. However, differences in participant case-
mix (e.g. in participant eligibility criteria), in variable definitions
and in data quality may also lead to substantial variation in model
performance. Accordingly, prediction model studies that are based
on large clustered datasets need to be sufficiently reported to
determine whether a developed or validated prediction model is
fit for purpose.
Methods: We describe the rationale and development process
of an extension of TRIPOD focusing on studies aimed at deve-
loping, validating or updating a prediction model that use
large clustered datasets with IPD from multiple studies or
datasets with data combined from multiple centers, regions or
countries.
Results: We pay specific attention to new items (N=10) and those
TRIPOD items that required adjustment (N=20) due to the fact that
participants are clustered within studies, practices, regions or
countries.
Conclusions: The rationale for each items is discussed, along with ex-
amples of good reporting and why transparent reporting is import-
ant, with a view to assessing risk of bias and clinical usefulness of
the developed or validated prediction model.
Keywords: Prediction, model, reporting, meta-analysis, individual par-
ticipant data
Invited talk: Rudi Pauwels
Session chair: Ann Van den Bruel
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Background: The ongoing Covid-19 pandemic was just a matter
of time to occur, given not only the long history of outbreaks
and pandemics but also the increase in their frequency and di-
versity during the past decades. A number of human and non-
human related factors are converging and driving these
outbreaks.
The causative viral agent, SARS-Co-2, spread around the world
in a matter of weeks, facilitated by transmission via the re-
spiratory airways and even by people who do not display
symptoms.
The world still had to predominantly react in crisis mode, exposing
gaps in pandemic preparedness at multiple fronts. It's a reminder
that a problem in one part of the world can rapidly become a prob-
lem in every part of the world where it impacts can be felt beyond
the medical and public health levels.
Methods: Therefore, we call for a quantum change in the world’s
approach, preparedness and response to pandemics, some posing
existential threats to society. Proper preparation should include
an international re-evaluation of the role of basic healthcare
around the world. The growing threat of future ‘unseen’ enemies
requires the adoption of a fundamental new mind set, one with
a longer time horizon, new technological tools, including more
advanced diagnostics that can be deployed locally, generate high
quality data rapidly and can be mass produced.
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Results: In order to respond better to future threats we should invest
and develop pan-viral therapies and more vaccine platforms that can
deliver solutions much more rapidly.
Conclusions: The Praesens Foundation and its partners are develop-
ing new technologies to assist in better surveillance, rapid response
to outbreaks and pandemics. This will be illustrated by a new mobile
laboratory example.
Keywords: Covid-19, pandemics, outbreaks, diagnostics, mobile labs
Session chair: Jan Y. Verbakel
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Background: Polygenic scores have become the standard for quanti-
fying genetic liability in the prediction of disease risks.
Methods: Polygenic scores are generally constructed as weighted
sum scores of risk alleles using effect sizes from genome-wide associ-
ation studies as their weights.
Results: The construction of polygenic scores is being improved with
more appropriate selection of independent single-nucleotide poly-
morphisms and optimized estimation of their weights, but other as-
pects of the research methods are receive little attention. Polygenic
prediction research is primarily done in large convenience samples,
with no questions asked about the relevance of the data, and, hence,
the relevance of the evidence that is being gathered.
Conclusion: In this lecture, I will review 15 years of polygenic risk re-
search and discuss lessons learned, lessons not learned, and promis-
ing directions for future research.
Keywords: Prediction, model, polygenic scores, evidence, genome-
wide association studies
Contributed session on diagnostic tests
Session chair: Mariska Leeflang
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Background: Screening programmes are evaluated using randomised
controlled trials with lengthy follow-up to morbidity, mortality and
overdiagnosis. The fast pace of advances in technology means these tri-
als are often based on outdated screening tests. A framework is needed
to guide how to evaluate proposed changes to screening tests.
We aimed to develop a practical framework to evaluate proposed
changes to screening tests in established screening programmes, by
synthesis of existing methods and development of new theory.
Methods: We identified published frameworks for the evaluation of
tests and screening programmes (n=64), and existing methods for
evaluating or comparing screening tests published in websites of na-
tional screening organisations from 16 countries. We extracted princi-
ples relevant to evaluation of screening tests. We then searched the
same websites for reviews evaluating changes to screening tests (n=
484). We analyzed the pathways through which these changes to
screening tests affected downstream health, and used these to adapt
and extend our framework.
Results: We did not find an existing framework specifically designed
for evaluation of screening tests across screening programmes. Our
proposed framework describes the pathways through which chan-
ging a screening test can affect downstream health. Some of these
pathways are already included in test evaluation frameworks, e.g. test
failures, test accuracy and incidental findings. Some are specific to
screening, such as overdiagnosis. We recommend study designs to
evaluate these pathways, and recommend a stepwise approach to
ensure proportionate review, with the most intensive evaluation re-
quired when there is a change to spectrum of disease detected.
Conclusions: We present a draft framework for evaluating changes in
screening tests. This framework adapts principles from diagnostic test
frameworks to the unique challenges of evaluating screening tests,
including the complexity in estimating the benefit of earlier detec-
tion following screen detection, and associated overdiagnosis.
Keywords: Screening, test, systematic review
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Background: Diagnostic accuracy studies with small numbers of
cases often use data-driven methods to simultaneously identify an
optimal cutoff and estimate its accuracy. When data-driven optimal
cutoffs diverge from standard or commonly used cutoffs, authors
sometimes argue that sample characteristics influence accuracy and
thus different optimal cutoffs are needed for particular population
subgroups.
We aimed to explore variability in optimal cutoffs identified and
diagnostic accuracy estimates from samples of different sizes and
quantify bias in accuracy estimates for data-driven optimal cutoffs,
using real participant data on Patient Health Questionnaire-9 (PHQ-9)
diagnostic accuracy.
Methods: We conducted a simulation study using data from an indi-
vidual participant data meta-analysis (IPDMA) of PHQ-9 diagnostic ac-
curacy (N studies = 58, N participants = 17,436, N cases = 2,322).
1000 samples of size 100, 200, 500 and 1000 participants were drawn
with replacement from the IPDMA database. (Figure 1) Optimal cut-
offs (based on Youden’s J) and their accuracy estimates were com-
pared to accuracy estimates for the standard and optimal cutoff of ≥
10 in the full IPDMA database.
Results: Optimal cutoffs ranged from 3-19, 5-14, 5-13, and 6-12 in
samples of 100, 200, 500, and 1000 participants, respectively. Com-
pared to estimates for a cutoff of ≥ 10 in the full IPDMA database,
sensitivity was overestimated by 10%, 8%, 6% and 5% in samples of
100, 200, 500, and 1000 participants, respectively. Specificity was
underestimated by 4% across sample sizes.
Conclusions: Using data-driven methods to select optimal cutoffs in
small samples leads to large variability in optimal cutoffs identified
and exaggerated accuracy estimates, although cutoff variability and
sensitivity exaggeration reduce as sample size increases. Researchers
should report accuracy estimates for all cutoffs rather than just
study-specific optimal cutoffs. Differences in accuracy and optimal
cutoffs seen in small studies may be due to the small sample sizes
rather than participant characteristics.
Keywords: Diagnostic test accuracy, bias, individual participant data
meta-analysis
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Background: Results of diagnostic test accuracy (DTA) meta-analyses
are often presented in two ways: i) forest plots displaying meta-
analysis results for sensitivity and specificity separately, and ii) Sum-
mary Receiver Operating Characteristic (SROC) curves to provide a
global summary of test performance. However other relevant infor-
mation on included studies is often not presented graphically and in
the context of the results.
We aimed to develop graphical enhancements to SROC plots to ad-
dress shortcomings in the current guidance on graphical presenta-
tion of DTA meta-analysis results.
Methods: A critical review of guidelines for conducting DTA system-
atic reviews and meta-analyses was conducted to establish and cri-
tique current recommendations for best practice for producing plots.
New plots addressing shortcomings identified in the review were de-
vised and implemented in MetaDTA [1].
Results: Two primary shortcomings were identified: i) lack of incorp-
oration of quality assessment results into the main analysis and; ii)
ambiguity with how the contribution of individual studies to the
meta-analysis are represented on SROC curves. In response, two
novel graphical displays were developed: i) A quality assessment en-
hanced SROC plot which displays the results from individual studies
in the meta-analysis using glyphs to simultaneously represent the
multiple dimensions of quality assessed using QUADAS-2; and ii) A
percentage study weights enhanced SROC plot which accurately por-
trays the percentage contribution each study makes to both sensitiv-
ity and specificity simultaneously using ellipses.
Conclusions: The proposed enhanced SROC curves facilitate the ex-
ploration of DTA data, leading to a deeper understanding of the pri-
mary studies including identifying reasons for between-study
heterogeneity and why specific study results may be divergent. Both
plots can easily be produced in the free online interactive applica-
tion, MetaDTA [1].
Keywords: Diagnostic test accuracy, meta-analysis, visualisation
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Background: Several biomarkers have been proposed for the diagno-
sis of sporadic Creutzfeldt-Jakob disease (sCJD), the most prevalent
form of human prion disease.
We identified and evaluated all relevant diagnostic studies for the
biomarker-based differential diagnosis (using serum or cerebrospinal
fluid biomarkers) of sCJD, and combined direct and indirect evidence
from these studies in a network meta-analysis.
Methods: We systematically searched Medline (via PubMed), Embase,
and the Cochrane Library. To be eligible, studies had to include the
established diagnostic criteria of sCJD and established diagnostic cri-
teria for other forms of dementia as reference standard. The studies
had to provide sufficient information to construct the 2×2 contin-
gency table (i.e., false and true positives and negatives). We regis-
tered the study protocol with PROSPERO, number CRD42019118830.
Risk of bias was assessed with the QUADAS-2 tool. We used a bivari-
ate model to conduct meta-analyses of individual biomarkers and to
estimate the between-study variability in logit sensitivity and specifi-
city. To investigate sources of heterogeneity, we performed subgroup
analyses based on QUADAS-2 quality and clinical criteria. We used a
Bayesian beta-binomial analysis of variance model for the network
meta-analysis.
Results: We included eleven studies, which investigated 14-3-3 (n=
11), NSE (n=1), RT-QuIC (n=3), S100B (n=3), and tau (n=9). Heterogen-
eity was high in the meta-analyses of individual biomarkers and dif-
ferent depending on the level of certainty of sCJD diagnosis. In the
network meta-analysis, 14-3-3 was the most sensitive, but among the
least specific test, while RT-QuIC was the most specific though
among the least sensitive test.
Conclusions: Our work shows the weaknesses of previous diagnostic
accuracy studies. Subgroup analyses will reveal if our results depend
on methodological quality of the studies or clinical criteria of the
patients.
Keywords: Blood, cerebrospinal fluid, neurodegeneration, diagnosis,
sporadic Creutzfeldt-Jakob disease
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Background: New diagnostic tests to identify a well-established dis-
ease state have to undergo a series of scientific studies from test
construction until finally demonstrating a societal impact. Tradition-
ally, these studies are performed with substantial time gaps in be-
tween. Seamless designs allow us to combine a sequence of studies
in one protocol and may hence accelerate this process.
Fig. 1 (abstract 23). Bias in accuracy results for samples of 100, 200,
500 and 1000 participants
Diagnostic and Prognostic Research 2021, 5(Suppl 1):7 Page 11 of 37
We performed a systematic investigation of the potential of seamless
designs in diagnostic research.
Methods: We summarized the major study types in diagnostic re-
search and identified their basic characteristics with respect to apply-
ing seamless designs. This information was used to identify major
hurdles and opportunities for seamless designs.
Results: 11 major study types were identified. The following basic
characteristics were identified: type of recruitment (case-control vs
population-based), application of a reference standard, inclusion of a
comparator, paired or unpaired application of a comparator, assess-
ment of patient relevant outcomes, possibility for blinding of test re-
sults. Two basic hurdles could be identified: 1) Accuracy studies are
hard to combine with post-accuracy studies, as the first are required
to justify the latter and as application of a reference test in outcome
studies is a threat to the study’s integrity. 2) Questions, which can be
clarified by other study designs, should be clarified before perform-
ing a randomized diagnostic study. However, there is a substantial
potential for seamless designs since all steps from the construction
until the comparison with the current standard can be combined in
one protocol. This may include a switch from case-control to
population-based recruitment as well as a switch from a single arm
study to a comparative accuracy study. In addition, change in man-
agement studies can be combined with an outcome study in dis-
cordant pairs. Examples from the literature illustrate the feasibility of
both approaches.
Conclusions: There is a potential for seamless designs in diagnostic
research.
Keywords. Test construction studies, accuracy studies, randomized
diagnostic studies, seamless design, blinding
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Background: Multivariate probit models are used to analyze corre-
lated ordinal data. In the context of diagnostic test accuracy without
a gold standard test, their use has been more limited. Multivariate
probit models have been used for the analysis of dichotomous and
categorical (>1 threshold) diagnostic tests in a single study, and for
the meta-analysis of dichotomous tests.
We aimed to (i) develop a model for the meta-analysis of multiple
binary and categorical diagnostic tests without a gold standard; (ii)
extend the model to enable estimation of joint test accuracy.
Methods: We extended proposed multivariate probit models for the
meta-analysis of diagnostic test accuracy, modelling the conditional
within-study correlations between tests. Dichotomous tests use bin-
ary multivariate probit likelihoods and categorical tests use ordered
likelihoods. We also showed how the model can be extended to esti-
mate joint test accuracy, to meta-analyse studies which report accur-
acy at distinct thresholds, and how to incorporate priors for the 'gold
standard' tests based on inter-rater agreement information. We fitted
the models using Stan which uses a state-of-the-art Hamiltonian
Monte Carlo algorithm.
Results: We applied the methods to a dataset in which studies evalu-
ated the accuracy of tests for deep vein thrombosis, where studies
included two dichotomous tests and one categorical test. We com-
pared our results to the original study, which assumed a perfect ref-
erence test. In Stan, we found estimation to be very slow for meta-
analyses which contained large studies with sparse data. We discuss
these computational issues and possible ways to improve scalability
by making use of recently proposed algorithms, such as calibrated
data augmentation Gibbs sampling.
Conclusions: We developed a model for the meta-analysis of mul-
tiple, categorical diagnostic tests without a gold standard. Unlike la-
tent class models, they can be extended to tackle a variety of
problems without having to inappropriately simplify or discard data.
Keywords: Meta-Analysis, diagnostic, test, accuracy, probit, imperfect,
gold, reference, thresholds, interrater, agreement
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Background: Most heart failure (HF) clinical prediction models (CPMs)
have not been independently externally validated.
We aimed to test the performance of HF CPMs using a systematic
approach.
Methods: We performed a systematic review to identify CPMs pre-
dicting outcomes in HF, stratified by acute and chronic HF CPMs. Ex-
ternal validations were performed using individual patient data from
8 large HF trials. CPM discrimination (c-statistic, % relative change in
c-statistic) as well as calibration (Harrell's E, E90, net benefit) was esti-
mated for each CPM with and without recalibration.
Results: Of 135 HF CPMs screened, 24 (18%) were matched on popu-
lation, predictors and outcomes to the trials and 42 external valida-
tions were performed. The median derivation c-statistic of acute HF
CPMs was 0.76 (IQR, 0.75-0.8), validation c-statistic was 0.67 (0.65,
0.68) and model-based c-statistic was 0.68 (0.66, 0.76), demonstrating
that most of the decrement in model performance was due to nar-
rower case-mix in the validation cohort compared with the develop-
ment cohort. The median derivation c-statistic for chronic HF CPMs
was 0.76 (0.74, 0.8), validation c-statistic 0.61 (0.6, 0.63) and model-
based c-statistic 0.68 (0.62, 0.71), thus decrement in model perform-
ance was only partially due to case-mix heterogeneity. The median E
(standardized by outcome rate) was 0.5 (0.3, 2.2) for acute HF CPMs
and 0.6 (0.3, 0.7) for chronic HF CPMs. Updating the intercept alone
led to a significant improvement in calibration in acute HF CPMs, but
not chronic HF CPMs. Net benefit analysis showed potential for harm
in using CPMs when decision threshold was not near the overall out-
come rate but this improved with model recalibration (Table).
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Conclusions: A small minority of published CPMs were matched to
clinical trial datasets. For acute HF CPMs, discrimination is largely pre-
served after adjusting for case-mix; however, model updating is re-
quired for both acute and chronic HF CPMs.
Keywords: Clinical prediction model, heart failure, mortality
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Background: Clinical prediction models (CPMs) are increasingly de-
veloped and validated using electronic health records (EHRs) since
they provide rich, longitudinal information on a patient’s interactions
with healthcare services. The analysis of such data is not, however,
without challenges. Specifically, the observation process of EHRs is
dependent on the underlying health status of the individual, which
not only leads to irregularly collected information, but importantly
means that the type, timing, and frequency of data collection could
be informative with respect to a patient’s health status. This is re-
ferred to as “informative presence” and “informative observation”. In-
formative presence/observation may be an opportunity, as the
additional information contained within the observation process
could improve accuracy of prediction models.
This project aims to synthesise the existing analytical methodology
that could be used to allow CPMs to learn from “informative pres-
ence” and “informative observation”. In doing so, we aim to identify
remaining methodological challenges in this area.
Methods: A systematic literature search was conducted by two inde-
pendent reviewers. Keywords were identified and used to search
Embase, MEDLINE and Web of Science. Articles were screened based
on title and abstract at stage one, and full texts at stage two for any
remaining papers.
Results: All methods (within 37 papers) discovered during this review
broadly fall under three categories; methods which use derived infor-
mation about the observation process as model predictors (e.g.
counts of observations or visits), methods which make indirect use of
the observation process via a latent structure (e.g. through random
effects in joint models), or methods that model under informed
missingness.
Conclusions: Methodology to incorporate informative presence/ob-
servation in CPMs is beginning to emerge, and shows promise in im-
proving the performance of prediction models. However this is still
an underdeveloped area, and further work should explore where
each method improves predictive accuracy.
Keywords: Informative, observation, presence, absence, prediction,
model
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Background: Prediction models are often developed using a multi-
variable regression framework (e.g. logistic, survival, or linear regres-
sion), which provides an equation to estimate an individual's
outcome probability (for binary or time-to-event outcomes) or out-
come value (for continuous outcomes) conditional on values of mul-
tiple variables (‘predictors’). When estimating such equations using a
particular dataset, standard estimation techniques are often used, in
particular ordinary least squares or maximum likelihood estimation.
However, when applied in new individuals, these fitted equations
tend to produce optimistic (i.e. too extreme) predictions; that is, the
predicted outcome probability (from logistic or time-to-event regres-
sion models) or the predicted outcome value (from linear regression)
for new individuals is too far from the mean for some individuals.
This is a particular concern when the number of predictors is large
relative to the sample size, such that overfitting is a concern.
Methods: To address the issue of overfitting, penalisation estimation
techniques are increasingly being recommended, especially for situa-
tions where the effective sample size is low. These include uniform
shrinkage (e.g. estimated via bootstrapping), the lasso, elastic net,
and ridge regression. Many researchers believe such methods resolve
the issue of overfitting entirely.
Results: In this talk we highlight that penalisation methods are no
substitute for obtaining large sample sizes for model development.
In particular, through examples, simulation and analytic reasoning,
we show that shrinkage and penalty factors are typically estimated
with large uncertainty, especially in small development datasets
where the potential for overfitting is large.
Conclusion: We discuss and illustrate approaches to reduce this un-
certainty for the lasso, elastic net and ridge regression, and reinforce
guidance for how to derive the sample size needed to develop a
model.
Keywords: Prediction, shrinkage, penalisation, uncertainty
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Background: Polygenic risk scores (PRS) can be used in breast cancer
(BC) risk stratification to improve current screening programs. Re-
cently, Läll et al. developed a PRS based on the Estonian Biobank
Table 1 (abstract 29). Effects of updating on net benefit by decision
curve analysis. Threshold refers to decision threshold and Prev./2 refers
to the net benefit when the decision threshold is half the event rate,
prevalence means the decision threshold is at the outcome prevalence
and Prev.*2 refers to decision threshold at twice the outcome
prevalence.
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(EstBB) cohort [1]. We analyzed how well this PRS performs in estimat-
ing women’s future risk of developing BC.
We aimed to estimate the cumulative BC incidence for women in the
EstBB cohort, using the prevalence-based PRS[1] as predictor together
with year of cohort-entry, age, BMI, smoking status, educational level
and prevalent co-morbidities. To evaluate the prognostic perform-
ance of PRS-based risk.
Methods: We included data on 30,312 women from the EstBB cohort,
between 20-89 years and without a history of BC. We estimated ab-
solute 3 and 5-year PRS-based risk with a Cox Proportional Hazards
model, retaining PRS and age as covariates. Performance of the age-
adjusted PRS-based risk was assessed in terms of cross-validated cali-
bration, discrimination, and reclassification.
Results: Calculated risks derived from the age-adjusted PRS-model
were consistent with the observed cross-validated 3-year cumulative
incidence of 0.33% and 5-year cumulative incidence of 0.61% for the
entire cohort. The AUC was 0.720 (95% CI: 0.675 to 0.765) for 3 years
and 0.704 (95% CI: 0.670 to 0.737) for 5 years. Compared to an age-
only model, this was just 0.022 higher for 3 years and 0.023 higher
for 5 years. Reclassification analysis, using a 1% risk cut-off, showed
that few but overall more women were correctly vs incorrectly reclas-
sified (3-year NRI 0.094; 5-year NRI 0.0527).
Conclusion: Despite good calibration, we found modest incremental
performance improvement of the PSR-based risk compared to age-
based. A considerably larger study would be needed to assess
whether the PRS could meaningfully contribute to the development
of more efficient screening strategies.
Keywords: Prognostic accuracy, Breast cancer, Polygenic risk score,
Precision screening, Risk stratification, Medical test evaluation, Bio-
marker evaluation, Performance measures.
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Background: Prognostic models predict outcome for people with an
underlying medical condition. Many conditions are typified by recur-
rent events such as seizures in epilepsy. Prognostic models for recur-
rent events can be utilised to predict individual patient risk of
disease recurrence or outcome at certain time points.
Methods: Methods for analysing recurrent event data are not widely
known or applied in research. Most analyses use survival analysis to
consider time until the first event, meaning subsequent events are
not analysed and key information is lost. An alternative is to analyse
the event count using Poisson or Negative Binomial regression. How-
ever, this ignores the timing of events.
Results: Therefore, a systematic review on methodology for analysing
recurrent event data in prognostic models is ongoing. Results from
this review will identify methods commonly used in practice. Infor-
mation such as the event rate of the underlying condition will be col-
lected to determine whether model choice might be influenced by
this factor.
Conclusions: Results from this review will be presented including a
summary of each method identified. The results will be the first step
towards a toolkit for future analysis of recurrent event data.
Keywords: Prognostic models, systematic review, recurrent event
data
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Background: A gulf exists between the number of prognostic models
developed and those effectively adopted as clinical tools. Bridging
this gap requires recognition that a tool will not sit in isolation, but
be integrated into an often complex clinical system. Utility therefore
rests on both providing accurate predictions in a target population,
and on understanding a tool's role and acceptability in a clinical
system.
The OxMIV prediction model for violence in severe mental illness has
been internally and externally validated using Swedish population
registers.[1] The current project aims to externally validate and de-
velop OxMIV as a clinical tool for UK community mental health teams
who engage individuals with first-episode psychosis. This study will
examine how OxMIV can be used in a clinical setting- and specifically
its clinical acceptability, to develop a framework for its implementa-
tion and wider evaluation.
Methods: Mixed methods are used to examine the process of inte-
grating OxMIV into community mental health teams in two counties.
Interviews with 20 multidisciplinary clinicians focus on acceptability
and barriers to use. Approaches to examining uptake, reach and util-
ity are piloted using structured data from electronic records.
Results: Pilot work demonstrated the feasibility of using routine data
for validation, and showed 1 in 10 individuals under the care of these
services were arrested for violence in 12-months, but no structured
framework currently exists to determine risk. Preliminary findings
from work to develop OxMIV for this role will be discussed, focusing
on transferrable themes pertinent to the clinical translation of predic-
tion models.
Conclusions: These will include service management perspectives,
interface with electronic systems, risk communication, decision path-
ways, and clinician views on the desirable properties of a usable tool.
Keywords: Prediction, model, clinical, psychiatry, psychosis, violence
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Background: Measurement error of binary variables (misclassifica-
tion) is a common problem in the analysis of multiple data sources,
including individual participant data meta-analysis (IPD-MA). Mis-
classification may lead to biased parameter estimates, even when
the misclassification is entirely random. Available methods for ad-
dressing misclassification do not account for between-study hetero-
geneity in an IPD-MA.
We aimed to develop statistical methods that facilitate unbiased esti-
mation of logistic regression models for a one-stage IPD-MA, where
the extent and nature of misclassification may vary across studies.
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We focus on the estimation of predictor-outcome associations and
between-study heterogeneity.
Methods: We present Bayesian methods that allow misclassification
to be dependent on study-level and participant-level characteristics.
We illustrate this in an example of the differential diagnosis of den-
gue using two predictors, where the gold standard measurement for
one (muscle pain) is unavailable for some studies, which only mea-
sured a surrogate prone to misclassification. We present a simulation
study to assess bias, root mean square error (RMSE), coverage and
power in estimating the muscle pain-dengue association.
Results: In the example, our methods yielded estimates with less
error than analyses naive with regard to misclassification or based on
gold standard measurements alone. Minor differences were observed
in the estimates of heterogeneity of the muscle pain-dengue
association.
In our simulations, adjusting the one-stage IPD-MA models for mis-
classification lead to valid estimates of the adjusted predictor-
outcome association, with less RMSE, greater power and similar
coverage compared to an analysis restricted to available gold stand-
ard measurements.
Conclusion: Our proposed framework can account for the presence
of predictor misclassification in IPD-MA. It requires that 1) some stud-
ies supply IPD for the surrogate and gold standard variables and 2)
misclassification is exchangeable across studies conditional on ob-
served covariates (and outcome). Further work is needed for other
types of misclassification.
Keywords: Meta-analysis, misclassification, measurement error,
individual-participant-data (IPD)
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Background: Advances in artificial intelligence (AI)/machine learning
(ML) have attracted significant attention in recent years for their po-
tential applications in healthcare. A vast body of literature has been
published proposing AI/ML-based solutions for disease detection,
classification, prediction, or even as therapeutic interventions. How-
ever, there are concerns that the quality of evidence has not been
sufficiently robust to support safe and effective deployment of AI al-
gorithms in clinical care. In this talk, some of the major limitations of
reporting in clinical AI studies will be presented.
Methods: To address this urgent evidence gap, several new reporting
guidelines have been developed or are currently in development.
The first of these, published in September 2020, is the SPIRIT-AI
(Standard Protocol Items: Recommendations for Interventional Trials
–AI) and CONSORT-AI (Consolidated Standards of Reporting Trials–AI)
extensions for clinical trials evaluating AI interventions.
Results: SPIRIT-AI and CONSORT-AI include recommendations which
are AI-specific, such as asking authors to provide clear descriptions of
the AI system, including instructions and skills required for use, the
operational environment in which the AI intervention is integrated,
the handling of input and output data of the AI system, the human–
AI interaction and provision of an analysis of error cases.
Conclusion: SPIRIT-AI and CONSORT-AI will help promote transpar-
ency and completeness of studies in this area. It will assist editors
and peer reviewers, as well as the general readership, to understand,
interpret and critically appraise the quality of clinical trial design and
risk of bias in the reported outcomes.
Keywords: Artificial intelligence, machine Learning, clinical trials, ran-
domised controlled trials, protocol, reporting guidelines
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Background: Guidelines recommend identifying in early pregnancy
women at elevated risk of pre-eclampsia. Existing prediction tools
perform poorly among nulliparous women.
We aimed to 1) develop and validate a pre-eclampsia risk prediction
model for nulliparous women. 2) compare the model’s performance
against the existing NICE approach.
Methods: This retrospective cohort study included all nulliparous
women who gave birth in three public hospitals, Western-Sydney-
Local-Health-District, Australia, 2011-2014. Using births from 2011-
2012, we performed multivariable logistic regression incorporating
established maternal risk factors to develop, and internally validate,
the “Western Sydney (WS) model”. The WS model was externally vali-
dated using births from 2013-2014, assessing its discrimination and
calibration. We fitted the final WS model for all births from 2011-
2014, and compared its accuracy with the NICE approach.
Results: Among 12,395 births, 293 women (2.4%) had pre-eclampsia.
The WS model included: maternal age, BMI, ethnicity, multiple preg-
nancy, family history of pre-eclampsia, autoimmune disease, chronic
hypertension and chronic renal disease. In the validation sample (N=
6201), the model c-statistic was 0.70 [95% CI 0.65–0.75], suggesting
good discrimination. The observed:expected ratio for pre-eclampsia
was 0.91, and the Hosmer-Lemeshow p-value of 0.20 suggesting
good calibration. In the entire sample (N=12,395), 374 (3.0%) women
had a WS model-estimated pre-eclampsia risk ≥8%, the risk-threshold
for considering aspirin prophylaxis. Of these, 54 (14.4%) developed
pre-eclampsia (sensitivity 18% [14–23], specificity 97% [97–98]). Using
the NICE approach, 1173 (9.5%) women were classified as high-risk,
of which 107 (9.1%) developed pre-eclampsia (sensitivity 37% [31-
42], specificity 91% [91–92]). The final model showed similar accuracy
to NICE approach when using a lower risk-threshold ≥4%.
Conclusions: This WS risk model achieved modest performance for
pre-eclampsia prediction in nulliparous women. Although not super-
ior to the NICE approach, the WS model has the advantage of provid-
ing individualised risk-estimates to inform decisions for pregnancy
surveillance and aspirin prophylaxis.
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Background: Studies addressing diagnostic and prognostic predic-
tion models are abundant in many clinical domains. At the same
time, many systematic reviews showed that the quality of reporting
of prediction model studies is suboptimal.[1] Due to the increasing
availability of larger, routinely collected and complex data, and the
rising application of Artificial Intelligence (AI) and Machine Learning
techniques (ML) for clinical predictions, the number of prediction
models is expected to increase even further. These AI/ML-based pre-
diction model studies are often labeled as a "black box" and not
much is known yet about the quality of reporting.
The aim of this systematic review is to evaluate the reporting and
methodological conduct of prediction model studies that applied AI/
ML techniques for model development or validation.
Methods: Our protocol was registered in PROSPERO (CRD42019161764). A
search was performed in January 2020 to identify primary studies develop-
ing and/or validating prediction models using any AI/ML methodology
across all medical fields. Studies were included if predicted patient-related
outcomes, used any study design and were published in 2018-2019. We
assessed (1) the quality of reporting by measuring the adherence to Trans-
parent Reporting of a multivariable prediction model for Individual Progno-
sis or Diagnosis guideline (TRIPOD) and (2) the risk of bias in prediction
model development or validation using the Prediction model Risk of Bias
Assessment Tool (PROBAST).
Results: Initial results from the review will be presented, stratified by
medical field and prevalent AI/ML methods.
Conclusions: Emerging issues will be discussed, as well as the neces-
sity for specific reporting (TRIPOD-AI/ML) and risk of bias (PROBAST
AI/ML) assessment for AI/ML-based prediction model studies.
Keywords: Systematic review, machine learning, prediction
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Background: The Cox proportional hazards model is a commonly
used method when developing prognostic prediction models using
time-to-event data. In the presence of competing risks - events that
might prevent the occurrence of the event of interest – using a Cox
model leads to predicted probabilities that are too high. Thus
methods that account for competing risks, such as the Fine-Gray
model, are preferred. However, fitting this model is computationally
complex, particularly when used in combination with multiple imput-
ation and fractional polynomials. This poses a significant challenge
when developing prediction models in big databases.
We aimed to describe prediction modelling approaches that minim-
ise computation time, without compromising model validity, in a
large dataset of electronic health records.
Data: Data from the Clinical Practice Research Datalink were used to
create prognostic models for adverse events related to antihyperten-
sive medication, treating death as a competing event (prevalence
10%). The dataset included 1,773,224 patients and 40 predictors.
Methods/Results: A multivariable competing risk model developed
using the stcrreg command in STATA 16 (8 cores) required approxi-
mately two weeks to converge using an 8 core 32GB, i9 PC. Compu-
tation time was reduced to less than one day when estimating
regression coefficients using the R package fastcmprsk, which uses a
forward backward scan algorithm: this is more efficient than the
Newton-Raphson method. Robust bootstrap confidence intervals
were estimated using the percentile method. Fractional polynomial
transformations were computationally prohibitive, thus variable
transformations were modelled with the use of Cox regression, pro-
viding a good approximation of the relationship.
Conclusions: Computational obstacles to correctly account for com-
peting risks in clinical prediction models can be overcome by com-
bining fast algorithms, robust bootstraps and approximate fractional
polynomials transformations. We are currently investigating how to
optimise the use of the Fine-Gray model in conjunction with multiple
imputation.
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Background: Measurement error in biomarkers is best estimated in
Biological Variability Studies (BVS) where individuals have repeated
measures both at the same and at different time points. However,
BVS are not always feasible. We investigate whether measurement
error can be estimated using routine data from biomarker monitor-
ing programmes by application of a method known as the
variogram.
We aimed to demonstrate the potential of the variogram using
open-source monitoring programme data of serum albumin mea-
surements on stage 2-4 primary biliary cirrhosis patients.
Methods: Variation in measurements from patients over time in-
cludes three components: true differences at baseline between-
patients; true changes from baseline within-patients (‘signal’); and
measurement error (‘noise’). The variogram considers differences
within-patients computed between baseline and each follow-up
point; the variances of these differences increase at a rate dependent
on the magnitude of the within-patient variability. We grouped mea-
surements by year, and assigned weights according to the closeness
of the actual time to the midpoint using a Gaussian kernel approach.
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Weighted variances of differences in serum albumin were calculated
per time. The variogram is a plot of weighted variance of differences
(y-axis) against time (x-axis), with a fitted line estimated by linear re-
gression, weighted according to sample size. Extrapolation of the fit-
ted line to intersect the y-axis was used to estimate the
measurement error (‘noise’).
Results: The measurement error (‘noise’) estimate was 0.10 (gm/dL)2.
(Figure 1) ‘Signal’ first surpassed ‘noise’ at five years; the variance of
differences at one year was estimated almost entirely ‘noise’. Such re-
sults from weighted variogram analyses could be used to help define
optimal measurement timings for monitoring programmes.
Conclusions: Weighted variogram analyses have potential for appli-
cation where health status changes are unlikely; care should be exer-
cised in implementation, particularly related to bias from dropout.
Keywords: Variogram, variability, monitoring, measurement error
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Background: Health care data often has a hierarchical structure with
observations at different group levels (e.g., regions, hospitals, pa-
tients). Most commonly applied statistical models either combine the
data to estimate an average effect (complete pooling) or partition
the data to estimate a separate effect for each group (no pooling).
Such models treat the between-group variance implicitly as either
zero (i.e., complete pooling) or infinity (i.e., no pooling).
We seek statistical models that balance the trade-off between zero
and infinite between-group variance and, as a result, incorporate
both between- and within-group information in the group-level
estimates.
Methods: Bayesian hierarchical models account for the uncertainty in
the estimate of the between-group variance through partial pooling.
That is, group-level effects are estimated by taking into account the
uncertainty about the estimates. For groups with few observations
(or few information), the estimates are closer to the estimate from
complete pooling. Instead, for groups with many observations, the
estimates are closer to the estimate from no pooling. This principle is
called shrinkage and can be thought of as pulling group-level esti-
mates towards the population mean when uncertainty in the esti-
mate is high.
Results: We apply Bayesian hierarchical models in different contexts
of personalized health care. Thereby, hierarchical models reveal that
patient-specific effects can be estimated precisely for patients with
many observations, while the estimate for patients with few observa-
tions are pulled towards the patient-average.
Conclusions: Our applications demonstrate the advantages of Bayes-
ian hierarchical models for personalized health care. Results from
such models entail important implications for medical practitioners.
They inform physicians about patients where personalized treatment
is more likely to be successful and, vice versa, where a common
treatment should rather be administered because the range of pos-
sible treatment effects is too large.
Keywords: Bayesian hierarchical models, patient-specific effects, per-
sonalized health care
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Background: Dealing with multiple thresholds in diagnostic accuracy
meta-analysis can be challenging. We applied two modelling strat-
egies to summarize the available evidence of the diagnostic accuracy
of biomarkers for urinary tract infections in children.
Methods: We performed a systematic review and meta-analysis of
diagnostic test accuracy studies. We searched seven databases for
relevant articles. Eligible studies were prospective or retrospective
observational studies that reported the accuracy of urine or blood
biomarkers for urinary tract infections in children. Statistical analyses
were performed using R software. The bivariate random effects
model by Reitsma et al. [1] (‘mada’ package) and the model by Stein-
hauser et al. [2] ( ‘diagmeta’ package), taking into account multiple
thresholds per study, were both performed to calculate summary es-
timates for six biomarkers. We compared the output of two model-
ling strategies and reported the following characteristics: Area Under
the Curve (AUC) and clinical usability (clinically relevant threshold
providing a specificity of 0.90). For now, only results for C-reactive
protein (CRP) are shown, with the other biomarkers to be presented
at the MEMTAB 2020 symposium.
Results: We screened 9975 eligible studies, of which we included 62
in the review. For CRP, we found eight primary studies that reported
on 1 to 6 thresholds, ranging from 5 to 200 mg/l. Using the model
by Reitsma et al. [1] and Steinhauser et al. [2] the AUC was 0.705
(95%CI 0.581 – 0.812) and 0.748 (95%CI 0.617-0.856), respectively. To
reach a specificity of 0.90 (diagnosing UTIs), the clinically relevant
threshold was 25.33 mg/l, using the second method.
Conclusions: The ‘diagmeta’ package, implementing the method by
Steinhauser et al., allows specification of clinically relevant thresholds
according to the intended test aim. All primary study data, including
all reported thresholds, can be implemented in the model, resulting
in more reliable summary estimates.
Keywords: Meta-analysis, diagnostic, test, accuracy, biomarkers
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Background: Clinical prediction models (CPMs) can predict the risk of
health outcomes, such as disease onset or progression, for individual
patients. The majority of existing CPMs only harness cross-sectional pa-
tient information. Incorporating repeated measurements into CPMs
may provide an opportunity to enhance their performance.
We aimed to systematically review the literature to understand and
summarise existing approaches for harnessing repeated measure-
ments in the development of CPMs, and empirically investigate the
suitability of identified methods to real-world data using an illustra-
tive example in rheumatoid arthritis (RA).
Methods: Medline, Embase, and Web of Science were searched for arti-
cles reporting the development of a multivariable CPM for patient-level
prediction, and modelling repeated measurements of at least one pre-
dictor. Information was extracted on: the method, its specific aim, re-
ported advantages and limitations, and software available to apply the
method. For the illustrative example, CPMs were developed to predict
serious infections for RA patients starting anti-TNF therapy. Preliminary
analyses include a comparison of compatible cross-sectional and longi-
tudinal CPMs to predict a patient’s 12-month risk of serious infection at
various time points during follow-up.
Results: The database search revealed 217 relevant articles. Seven
methodological frameworks were identified: time-dependent co-
variate modelling, generalised estimating equations, landmark
analysis, two-stage modelling, joint-modelling, trajectory classifica-
tion and machine learning. Each of these frameworks satisfies at
least one of three aims: to better specify predictor-outcome rela-
tionship over time; to infer a covariate value at a pre-specified
time, and to account for the effect of covariate change. Identified
features in available RA observational cohort data motivated the
comparison of six applicable methods.
Conclusions: The applicability of identified methods depends on the
motivation for including longitudinal information and the method’s
compatibility with the clinical context and available patient data, for
both model development and risk estimation in practice.
Keywords: Dynamic prediction, clinical prediction models, longitu-
dinal data
43.
Adaptive sample size determination for the development of
clinical prediction models
Evangelia Christodoulou1, Maarten van Smeden2, Dirk Timmerman1,3,
Ewout Steyerberg4, Ben Van Calster1, 4
1Department of Development & Regeneration, KU Leuven, Leuven,
Belgium; 2Department of Clinical Epidemiology, Leiden University
Medical Center, Leiden, The Netherlands; 3University Hospitals Leuven,
Leuven, Belgium; 4Department of Biomedical Data Sciences, Leiden
University Medical Center, Leiden, Netherlands
Correspondence: Evangelia Christodoulou
Diagnostic and Prognostic Research 2021, 5(Suppl 1):43.
Background: For prediction model development, specifying an optimal
sample size in terms of predictive performance is an active area of research.
It is suggested that sample size depends on factors including event per
variable (EPV), outcome prevalence and prevalence of binary predictors.
We introduce a flexible approach for sample size determination
based on learning curves. Such curves monitor model performance
as new data comes in, to allow stopping patient recruitment when a
pre-specified stopping criterion has been reached. We illustrate the
approach using data for the diagnosis of obstructive coronary artery
disease (n=4888, 44% event rate).
Methods: We used logistic regression to develop prediction models
consisting of a-priori selected variables. We mimicked prospective
patient recruitment as follows. First, we fitted the model on 100 ran-
domly chosen patients, and estimated model performance metrics
using bootstrapping. Second, we sequentially added 50 random new
patients until we reached 3000 patients, and estimated model per-
formance at each step. We repeated the procedure 500 times to in-
vestigate variability. We built models once without addressing
nonlinear effects of continuous predictors (ML-LR), and once with re-
stricted cubic splines (RCS). We examined the required sample size
for the following possible stopping criteria: (1) calibration slope (CS)
0.9, (2) CS 0.9 and c-statistic increase (Δc) <=0.01, (3) CS 0.9 and
Δc<=0.01 for two consecutive sample sizes.
Results: When ML-LR was used, stopping criteria were met on aver-
age at sample sizes of 698 for criterion 1 (range 450-1000; EPV range
17-41), 1276 for criterion 2 (950-1550; 38-62), and 1368 (1050-1650;
41-66) for criterion 3. In contrast, EPV 10 was reached after 278 pa-
tients on average, with an average CS of 0.78. With RCS, the stopping
criteria required 35%-41% more patients.
Conclusions: Learning curves are important instruments to tailor
sample size to a specific context.
Keywords: Prediction model development, sample size, stopping
criteria
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Background: Meta-analysis of individual participant data (IPD-MA) of-
fers new opportunities for studying the generalizability of prediction
models across different settings and populations. The interpretation
of model performance estimates in IPD-MA is often challenging, be-
cause between-study heterogeneity may arise from invalid model co-
efficients and differences in (the distribution of) population
characteristics. Hence, the benefit of local model revisions may be
unclear.
We aimed to disentangle the effects of differences in case-mix and
invalid regression coefficients, to allow for the identification of repro-
ducibility of model performance and predictor effects.
Methods: We propose to standardize the c-statistic, calibration slope
and calibration-in-the-large for case-mix differences between samples
by applying propensity-weighting. The propensity scores are derived
using a (multinomial) membership model that predicts the originat-
ing sample of an individual in the IPD-MA.
We illustrate our methods in a motivating example on the validation
of eight diagnostic prediction models for detecting deep vein throm-
bosis (DVT) that may aid in the diagnosis of patients suspected of
DVT in 12 external validation data sets. We analyze the estimates of
prediction models’ performance across the external validation sets
with random effects meta-analysis.
Results: In the meta-analysis of c-statistics, summary estimates were
not affected much by standardization. However, standardization sub-
stantially reduced the between-study heterogeneity, indicating that
variation of the models’ discrimination across the validation studies
can partially be attributed to differences in case-mix, rather than in-
valid model coefficients.
Standardization increased the estimated between-study heterogen-
eity in calibration slopes. This implies that the predictor effects do
not reproduce well in new samples with the same case-mix
distribution.
Conclusions: Propensity score-based standardization may facilitate
the interpretation of (heterogeneity in) prediction model perform-
ance across external validation studies, guide model updating strat-
egies or show that the validation sample does not reflect the target
population of the model.
Keywords: Prediction model, performance, propensity score,
standardization, external validation
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Background: Test accuracy measures for primary care are often de-
rived from small, heterogeneous studies suffering from differential
verification bias.
We aimed to explore the potential of using routine primary care data
to derive test accuracy estimates of faecal calprotectin (FC) testing
for inflammatory bowel disease (IBD) compared to conventional and
tailored meta-analyses of published test accuracy studies.
Methods: FC tests in adult patients with no previous IBD diagnosis
from 2006-2016 were extracted from THIN. Multiple tests, tests with-
out numeric results, with missing units or units other than μg/g were
excluded. The reference standard was a coded record of IBD diagno-
sis or disease specific medication at three follow-up times. Sensitivity
analyses explored assumptions on test exclusions, reference standard
and patient selection. Results were compared to pooled estimates of
sensitivity and specificity using conventional and tailored meta-
analysis of studies from a recent systematic review.
Results: 7084/17466 FC tests were included. 4570 FC tests had no
subsequent diagnosis recorded. Longer follow-up had no impact on
the number of IBD diagnoses. The main methodological issues were
1) missing test results, 2) missing variables including indication for
testing, test/laboratory information and results from secondary care
testing, 3) misclassification of disease using clinical codes, 4) the in-
ability to confirm absence of disease. Study assumptions had a
greater impact on specificity than sensitivity. Sensitivity and specifi-
city were similar to pooled estimates from meta-analyses (Table 1).
The test positive rate was higher but IBD prevalence in FC tested pa-
tients was similar in routine data and published studies of similar
settings.
Conclusions: Test performance measures using routine data need to
be interpreted with caution considering study limitations. Triangula-
tion of tailored meta-analysis and routine data may provide evidence
sufficient to support decision making.
Keywords: Electronic health records, test accuracy, tailored meta-
analysis
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Background: In the UK, 1.4 million people live with undiagnosed and
untreated obstructive sleep apnoea (OSA) and are at an increased
risk of cardio-metabolic complications and diabetes. Polysomnogra-
phy (PSG) is the gold standard for the diagnosis of OSA but is expen-
sive, time-consuming and has long waiting lists. A questionnaire to
identify patients at high risk of OSA requiring further investigation
and treatment would be of great benefit.
We aimed to determine the best questionnaire for identifying adults
at high risk of OSA amongst different clinical cohorts accounting for
multiple questionnaires and multiple thresholds.
Methods: 31 studies reporting the diagnostic accuracy of the Berlin,
STOP or STOP-Bang questionnaires as a screening tool for moderate-
to-severe OSA were available for meta-analysis from two clinical co-
horts of patients: sleep clinic and surgical. Within each cohort ran-
dom effects bivariate binomial models were fitted to each
questionnaire. Where there was a difference in diagnostic ability be-
tween questionnaires we tested this using meta-regression. In the
surgical cohort, we accounted for multiple thresholds using the
methods of Steinhauser et al[1].
Results: In both the sleep clinic and surgical cohorts, meta-regression
including questionnaire as a covariate identified statistical differences
in sensitivity between STOP-Bang and Berlin. There was no evidence
of differences in specificity. Due to the large number of parameters
estimated when accounting for multiple thresholds we were only
able to fit two of the eight models proposed by Steinhauser et al[1].
Conclusions: Performing a coherent analysis under the frequentist
framework that is able to incorporate multiple questionnaires and
multiple thresholds across different clinical cohorts whilst avoiding
the well-known issues associated with multiple testing can be
Table 1 (abstract 45). Sensitivity and specificity of FC testing using
three methods
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challenging within the limits of current methodology, even with a
moderately sized dataset.
Keywords: Diagnosis, meta-analysis, screening
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Background: In the age of personalized medicine, prediction models are
becoming increasingly popular for risk stratification and informed treatment
decisions. Accessibility of large routine data collections and observational
cohorts facilitates the validation of existing prediction models and the de-
velopment of new ones.
We aimed to define necessary steps and to stress the importance of ini-
tial data analysis before running regression analysis (IDA-REG), assum-
ing that a data set has already passed an initial data cleaning stage.
Methods: Following a conceptional framework for IDA[1], we describe
3 mandatory and 3 optional steps of IDA-REG.
Results: IDA-REG focuses on informing an analyst about features in
the data that should be known to the data analyst in order to a)
properly interpret results of an analysis, b) make decisions on how to
present the results of an analysis, and c) adapt the statistical analysis
plan to avoid analysis errors. Mandatory steps include summaries of
univariate distributions of predictors and outcome variable, summar-
ies of bi- and trivariate distributions of predictors, and summaries of
patterns of missing values. Optional steps include investigation of
measurement error, investigation of levels of measurement (hierarch-
ies), and exploring unsupervised possibilities to reduce dimensional-
ity of regression models. The evaluation of associations of predictors
with the outcome is explicitly not part of an IDA-REG. We exemplify
IDA-REG by means of simulated and real data.
Conclusions: Appropriate graphical and analytical tools enable a re-
searcher to perform IDA-REG in order to avoid misinterpretation,
poor presentation and analysis errors. These necessary preparations
are too often forgotten by inexperienced data analysts. (253 < 300
words)
Keywords: Prediction, model, data screening
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Background: Pertussis or whooping cough is a highly contagious
vaccine preventable disease. Incidence of pertussis, has known a
steady decline after the introduction of pertussis vaccination never-
theless pertussis incidence increased over the past two decades in
many countries. The analysis of serial serological survey data can im-
prove our understanding about the dynamics of pertussis. However,
the development of assays for the detection of IgG antibodies in sera
entails that various assays have been used for different survey years.
We need comparable sero-epidemiological results for statistical and
mathematical models to estimate time-varying epidemiological
parameters.
We aimed to investigate the consequences of the uncertainty related
to the standardization of pertussis toxin IgG antibodies results from
three serological surveys conducted in Belgium (2002, 2006, 2013).
Methods: In each survey, 150 samples were selected such that the
range of the original values for IgG antibodies against pertussis toxin
was as best as possible covered. All 450 samples were then tested
using a magnetic bead-based multiplex immunoassay (MIA).[1] We in-
vestigated different models for the log-transformed values and con-
sidered also different strategies for outliers and censored data.
Results: The model choice for the standardization can be sensitive to
the strategy applied for outliers and censored data. The survey 2013
was originally already tested using MIA but at different concentra-
tions as the current study. The comparison with the re-tested 150
samples from 2013 together with validation data can be used to in-
vestigate intra-assay variability.
Conclusions: The uncertainty in the standardization of antibody titres
needs to be reflected in models aimed at estimating time-varying
epidemiological parameters, such as the force of infection, from serial
serological survey data.
Keywords: Sero-epidemiology, pertussis, assay comparison
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Background: The diagnostic value of C-reactive protein (CRP) for ap-
pendicitis has been extensively evaluated in specialist care, but not
in primary care.
We aimed to determine the (added) diagnostic value of CRP for ap-
pendicitis in children with acute abdominal pain in primary care.
Methods: A retrospective cohort study of children aged 4-18 years
who presented in general practices with acute abdominal pain and a
CRP test, between 2010 and 2016. CRP levels at first contact were
compared to the final diagnosis of appendicitis reported in the spe-
cialist reports within six weeks. Test characteristics of CRP were calcu-
lated for multiple thresholds. To evaluate the added value to history
and physical exam we compared the area under the receiver operat-
ing characteristics curves (AUC) and decision curves of two logistic
regression models: 1) basic model (six clinical features assessed by
the GP) and 2) basic model plus CRP.
Results: Of 1076 included patients, 203 (19%) were referred to specialist
care and 70 (7%) had appendicitis. The sensitivity and specificity of CRP for
a commonly used threshold of 10 mg/L was 0.87 (0.77-0.94) and 0.77 (0.74-
0.79) respectively. The sensitivity increased to 1.00 (0.89-1.00) when the
symptoms had lasted longer than 48 hours. Adding CRP to the basic model
of clinical features increased the AUC significantly from 0.81 (0.76-0.85) to
0.88 (0.84-0.91). The decision curve showed that the basic model plus CRP
had the highest net benefit at reasonable threshold probabilities (Figure 1).
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Conclusions: In primary care, CRP showed to have an added value to
history and physical examination in the diagnostic work-up of appen-
dicitis in children with acute abdominal pain. A value below 10 mg/L
in children with symptoms longer than 48 hours could safely rule out
appendicitis.
Keywords: CRP, appendicitis, primary care
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Background: Warfarin remains the most used oral anticoagulant in
sub-Saharan Africa. It has a narrow therapeutic index and highly vari-
able clinical response for a given dose and thus optimal dose predic-
tion is difficult.
We aimed to develop and validate a warfarin dose prediction model
for use in sub-Saharan African populations.
Methods: Multivariable linear regression models were fitted using
data from 364 patients. Starting with a list of potential variables, all
possible linear models were fitted, with the optimal models chosen
with reference to mean absolute error (MAE), mean absolute percent-
age error (MAPE) and logarithmic accuracy ratio. Bootstrap validation
was applied to correct overfitting and the final models were exter-
nally validated in a cohort of 690 patients. In both development and
external validation cohorts, we compared our models with current
warfarin initiation practice (fixed dose of 35 mg/week) and two
widely known dose prediction models.
Results: The final model included the three predictor variables age,
weight and target International Normalized Ratio, and gave MAE of
11.7 (95% CI, 10.5-12.9) mg/wk, MAPE of 14.4% and a log accuracy
ratio of 0.003. Ideal dose (predicted dose within 20% of actual dose)
was achieved in 42.6% patients. In external validation, MAE was 12.4
(11.5-13.5) mg/wk, MAPE 14.7%, log accuracy ratio 0.006 and ideal
dose was achieved in 41.4%. Based on all these metrics, our model
performed better than the two well-known models, and compared to
fixed dosing, it decreased the percentage of patients at high risk of
sub-optimal anticoagulation by 8.3% and 11.9% in the development
and validation cohorts respectively.
Conclusions: A dosing model has been developed for the first time
for Black African patients starting warfarin in South Africa and
Uganda. Its clinical utility is soon to be tested in a prospective study.
Keywords: Dose prediction, warfarin, anticoagulation, Black African,
personalized medicine
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Background: Normal Tissue Complication Probability (NTCP) models
predict the risk of radiation induced complications and can be used
to optimize dosage plans of radiation-based therapies to minimize
the risk of such complications. Dosage delivered to organs at risk
(OARs) surrounding the targeted tumor is often highly collinear (r2 >
0.8), inducing high variance on coefficient estimates. Consequently,
many NTCP models are developed using only a subset of relevant
OAR, especially for complex complications, like dysphagia, involving
many relevant OAR. Excluding OAR can be problematic when using
NTCP models for dosage optimization as it steers dosage towards ex-
cluded OAR.
We aimed to compare different methods to address collinearity with-
out degradation of model performance.
Methods: We compared five methods that constrain the coefficient
search space (reducing coefficient variance) for standard logistic re-
gression: Lasso, Ridge, principal component regression, dropout
regularization (random dropout of predictors during iterative model
fitting), and non-negativity constraints for OAR dosage coefficients.
Each method is empirically evaluated, using a 16-predictor logistic re-
gression NTCP model for dysphagia grade ≥2 (predictors are: primary
tumor location, and mean dose for 11 OARs).
Results & Conclusions: Table 1 shows similar AUROC and Brier across
methods, and similar calibration (in-the-large and slope) at cross-
validation. PCA and non-negativity constraints stand out in terms of
calibration at external validation. All methods reduce but still contain
one or more negative coefficients for OAR dosage variables except
when using non-negativity constraints (β+). If accepted for presenta-
tion, we expect to show results of combining PCA and non-
negativity constraints as well, as we concluded these methods to be
most beneficial for this use case based on these preliminary results.
Keywords: Collinearity, NTCP, radiotherapy, prediction, dysphagia
Fig. 1 (abstract 49). Decision curve for both models predicting
appendicitis.
Table 1 (abstract 51). Comparison of methods for a within-hospital 10-
fold-cross-validation (n=489) and an external validation (ndev=489, ntest=
143). Reported statistics (and standard deviations) are: the percentage of
negative OAR coefficients (%βOAR<0), area under the receiver-operating-
characteristic curve (AUROC), calibration in-the-large (CITL), calibration
slope (CSLOPE), and Brier score.
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Background: Assessing risk of bias and applicability (RoB) of included
studies is critical for interpreting meta-analysis (MA) results. RoB tools
for diagnostic, prognostic, and prediction studies include QUADAS-2
and PROBAST. However, individual participant data meta-analyses
(IPD-MAs) differ from aggregate-data MAs in that in IPD-MA, datasets
may include additional information, eligibility criteria may differ from
the original publications, and definitions for index tests/predictors
and reference standards/outcomes can be standardized across stud-
ies. Thus, tailored RoB tools may be needed.
We aimed to review how RoB is currently assessed in IPD-MAs, and
to examine QUADAS-2 and PROBAST, with the goal of developing
IPD-MA extensions for each tool.
Methods: We reviewed RoB assessments in IPD-MAs published in the
last 12 months. We then examined how QUADAS-2 (and in-progress
extensions) and PROBAST items might be evaluated in an IPD-MA
context; noting which items might be removed, edited, or added;
and hypothesized how results may be incorporated into IPD-MA
analyses.
Results: We observed that current IPD-MAs rarely and inconsistently
evaluate RoB, and most do not incorporate RoB judgements into
analyses. Our findings indicate using QUADAS-2 and PROBAST to as-
sess RoB of IPD datasets themselves, rather than study publications.
Certain items may need to be coded at the participant level (e.g.,
timing between index test/predictor and reference standard/out-
come), whereas others (e.g., quality of diagnostic tool) may apply
uniformly to an included study. Most analysis items (e.g., pre-
specification of thresholds and variables for analysis) may not be
relevant, as IPD-MA researchers perform the analyses themselves.
RoB results may be incorporated into analyses by conducting sub-
group analyses among studies and participants with overall low RoB
or by conducting formal interaction analyses with item-level RoB
responses.
Conclusions: Development and dissemination of IPD-MA extensions
for QUADAS-2 and PROBAST will lead to improved RoB assessments
in IPD-MAs of diagnostic, prognostic, and prediction studies.
Keywords: Risk of bias, applicability, QUADAS-2, PROBAST, individual
participant data meta-analysis
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Background: Selectively reporting accuracy results from only well-
performing cutoffs in studies of diagnostic or screening tests may re-
sult in biased estimates when synthesized. Extent of bias may differ
depending on the availability of a well-defined standard cutoff.
We compared bias in accuracy estimates and cutoff reporting pat-
terns for the Patient Health Questionnaire-9 (PHQ-9; well-defined
standard cutoff ≥10) and Edinburgh Postnatal Depression Scale
(EPDS; no standard cutoff, common cutoffs ≥10 to ≥13).
Methods: We analyzed subsets of datasets from two separate indi-
vidual participant data meta-analyses (IPDMAs) on PHQ-9 and EPDS
accuracy. Separately, for the PHQ-9 and EPDS, we used bivariate ran-
dom effects meta-analysis to compare accuracy estimates based on
published cutoffs only versus all cutoffs from all studies. We also
compared the number of published cutoffs below and above the
standard or common cutoffs in relation to study-specific “optimal”
cutoffs.
Results: For the PHQ-9 (30 studies, N = 11,773), published results
underestimated sensitivity compared to results for all cutoffs for cut-
offs below ≥10 (median difference: -0.06) and overestimated for cut-
offs above ≥10 (median difference: 0.07). EPDS (19 studies, N =
3,637) sensitivity estimates were similar for cutoffs below ≥10 (me-
dian difference: 0.01) but higher for published cutoffs above ≥13
(median difference: 0.14). Mean cutoff of all cutoffs reported among
PHQ-9 studies with optimal cutoffs below ≥10 was 8.8 compared to
11.8 for studies with optimal cutoffs above ≥10. 18 of 19 EPDS stud-
ies had optimal cutoffs below ≥13; those below ≥10 did not report
more cutoffs below ≥10 (mean cutoff: 9.9), but those with above ≥10
reported more above ≥10 (mean cutoff: 11.8).
Conclusions: Selective cutoff reporting and resulting bias in accuracy
estimates were more pronounced for the PHQ-9 than EPDS. Re-
searchers evaluating diagnostic accuracy of screening tools should
report results for all relevant cutoffs.
Keywords: diagnostic test accuracy, individual participant data meta-
analysis, meta-analysis, selective cutoff reporting, publication bias
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Background: The diagnosis of giant cell arteritis (GCA) can be con-
firmed by temporal artery biopsy (TAB). However, TAB is insensitive;
therefore, GCA is often diagnosed on clinical grounds despite nega-
tive TAB. The prevalence of misdiagnosis in this patient group is un-
known. GCA has a strong HLA genetic association [1] that might be
used as an umpire test.
We aimed to estimate the prevalence of misdiagnosis of GCA among
patients diagnosed with GCA without a positive TAB.
Methods: Cases came from UK GCA Consortium, which recruited pa-
tients with a firm clinical diagnosis of GCA. Population control data
came from the Wellcome Trust Case Control Consortium. Cases were
genotyped using an Illumina genotyping chip [1]. Case and control
genomes were jointly imputed using SNP2HLA. A genetic association
analysis was carried out, adjusting for the first ten principal compo-
nents. Misdiagnosis rate was estimated using observed frequencies
of nominally-associated variants in the HLA region (P<0.1), assuming
the GCA patient group was composed of a mixture of genuine GCA
cases and misdiagnosed cases.
Results: 663 patients diagnosed with GCA (356 with a positive TAB,
147 with a negative TAB and 160 with no TAB result) were compared
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with 2619 controls. Allele frequencies of 470 variants in the HLA re-
gion were compared. The estimated proportion of patients misdiag-
nosed as GCA was 67% in the negative-TAB group and 33% in the
group without TAB result.
Conclusions: The proportion of patients misdiagnosed with GCA can
be estimated under certain assumptions. We assumed accurate
reporting of TAB and that the cases with genuine GCA with and
without a positive TAB are genetically similar. This method could be
extended to similar diseases with an insensitive but highly specific
reference-standard test and strong genetic susceptibility associations.
Keywords: Imperfect reference standard, umpire test, misdiagnosis,
genetic association
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Background: Tuberculosis meningitis (TBM) represents 2-5% of the
global annual TB burden, or 0.2-0.5 million cases[1], a highly uncertain
prevalence estimate as there is no reliable gold standard to defini-
tively classify it. Despite recognition of the imperfect nature of
employed reference standards, naïve methods used to evaluate ac-
curacy of new TBM tests, e.g. composite reference standards (CRS),
do not account for the uncertainty in their accuracy. Consequently,
estimates of TBM diagnostic test sensitivity and specificity based on
such methods may be biased.
We used Bayesian latent class analysis to estimate Xpert MTB/RIF
(Xpert) accuracies for diagnosing TBM and compared these to esti-
mates from multiple CRSs.
Methods: An existing dataset of all adults presenting to a tertiary
care hospital with suspected extrapulmonary tuberculosis in New
Delhi, India, in 2012 was analysed. We selected individuals undergo-
ing investigation for TBM with valid results for bacterial culture,
smear microscopy, cytopathology/histopathology, and Xpert. A heur-
istic model was created to understand relationships between latent
classes and tests, with a random effect to denote bacterial burden
(Figure 1). A Bayesian approach was used to estimate the latent class
model. Multiple CRSs were defined by increasing numbers of positive
component tests. Analyses were performed using RJAGS (Version 4-
8) through R-studio (3.5.2).
Results: Using 224 patients with suspected TBM, Xpert sensitivity and
specificity were 51.2% (95%CrI:34.2-71.0) and 99.6% (95%CrI:97.7-
100). Xpert sensitivity varied dramatically by CRS definition: sensitivity
was 33% (95%CI:98-100) with a CRS of any one positive test result,
increasing to 52% (95%CI:34-69) with two positive results, and reach-
ing 100% (95%CI:48-100) with all four positive results.
Conclusions: Unlike CRSs, Bayesian latent class analysis produces es-
timated test accuracies that incorporate reference standard uncer-
tainty and conditional dependence for TBM, the most severe form of
tuberculosis.
Keywords: Latent class analysis, diagnostics, tuberculosis meningitis,
composite reference standards
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Background: Standard studies comparing diagnostic tests measure
diagnostic test accuracy. Some trials also provide information on
additional outcomes such as time to diagnosis and the number
of additional tests in patient pathway. Ideally diagnostic tests
would be compared as interventions in randomised controlled tri-
als (RCTs). However RCTs for comparison of diagnostic tests as in-
terventions can be problematic to design and run. Problems
include long time periods required for studies following patient
outcomes during which either test or treatment pathways
change, high numbers of patients required, high costs, ethical is-
sues about randomizing to receive tests, difficulty understanding
role of diagnostic test as complex intervention, plus other bar-
riers. We present three examples where we have measured how
tests affect patient management decisions within diagnostic ac-
curacy trials.
We aimed to describe methods and insight from three clinical trials
recently completed measuring the impact of diagnostic tests on pa-
tient management.
Methods: Three trials, each comparing alternative diagnostic tests
or diagnostic test pathways against a reference standard of nor-
mal clinical practice have been designed to collect patient man-
agement decisions. In each patient management decisions based
on the alternative pathways are reported based on eight or ten
alternative management options. STREAMLINE COLON and LUNG
compare whole body MRI to current NICE recommended path-
ways for detection of metastases at diagnosis of colon and lung
cancer respectively. METRIC compares ultrasound and MRI for
diagnosing the extent and activity of Crohn’s disease in newly di-
agnosed and relapsed patients.
Results and discussion: Additional analysis, subsequent to prior
main trial results, are ongoing to explore impact of patient man-
agement decisions by linking detailed analysis of patient diagno-
sis and management decisions. These three trials provide insight
into the design, analysis issues and how measuring patient
Fig. 1 (abstract 55). Heuristic model for TBM showing assumed
relationships between latent classes (ovals), diagnostic test results
(rectangles), and random effect (circle).
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management decisions in a clinical trial can provide important in-
formation on the role and uses of diagnostic tests.
Keywords: Diagnosis, impact, patient management, accuracy, clinical
trial
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Background: Incorrect labeling of patients can hamper model devel-
opment resulting in sub-optimal clinical decision support systems
(CDSS) that can misclassify patients. During model development, pa-
tients are labeled, using guidelines postulated in literature, based on
their retrospective routine electronic health record (EHR) data. Acute
kidney injury (AKI) is identified by the Kidney Disease Improving Glo-
bal Outcomes (KDIGO) criteria using changes in serum creatinine
measurements. Creatinine measured at the emergency department
(ED) is compared to a `baseline` measurement extracted from the
patient's medical history. Depending on the definition of 'baseline'
patients can be misclassified by the model. We evaluated the effect
of multiple baseline-definitions on AKI prevalence in the ED.
Methods: 47.190 ED-visits (19.956 patients) in the UMC Utrecht with
a prior creatinine measurement between 2011-2019 were included
from the Utrecht Patient-Orientated Database. An increase of 26,5
μmol/L creatinine between baseline-value and the ED-value was used
as AKI definition (KDIGO). We analyzed four baseline-definitions: low-
est, mean, median and most recent value from the patient’s EHR.
Multiple time intervals were used (≤365 days prior ED-presentation)
to determine AKI-prevalence.
Results: The longest interval (365 days prior presentation) in combin-
ation with the lowest value as baseline resulted in the highest AKI-
prevalence (12,65%) compared to the mean (4,23%), median (4,8%)
and the most recent value (4,5%). Iteratively reducing the time win-
dow for extracting the creatinine measurement only showed extreme
differences when using the lowest value as baseline. In comparison
with the shortest interval (45 days) the longest interval increased the
prevalence with 10,92% (5.151/47.190 additional AKI labels).
Conclusions: Using a specific definition of baseline, results in signifi-
cantly different AKI prevalence in the ED. Adequate translation of
guidelines to diagnose disease is crucial for accurate patient labeling
to reduce misclassification by the model and to improve CDSS's ac-
curacy to better support clinical decision making by treating
physicians.
Keywords: Acute kidney injury, electronic health records, outcome
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Background: Using prediction models to calculate a patients indi-
vidual risk in clinical practice, requires complete information on
all predictors in the prediction model. Unfortunately, routine care
data is often incomplete due to a variety of reasons. Although
several methods for real-time imputation of missing predictor
values exist, they often require immediate access to data from
other similar patients and are therefore not directly suitable for
routine care.
We aimed to develop and evaluate methods for real-time imput-
ation of missing predictor values in routine clinical care when ap-
plying prediction models to individual patients.
Methods: We describe (i) mean imputation (where missing
values are replaced by the sample mean), (ii) joint modeling im-
putation (JMI, where we use a multivariate normal approxima-
tion to generate patient-specific imputations) and (iii)
conditional modeling imputation (CMI, where a multivariable im-
putation model is derived for each predictor from a population).
We compared the imputation methods by applying a previously
developed prediction model (predicting 10-year risk of recurrent
vascular disease) in a dataset with 3,880 participants from the
Utrecht Cardiovascular Cohort in which missing predictor values
were simulated. Furthermore, comparing true and imputed pre-
dictor values, the root mean squared error (RMSE) and coverage
of the 95% confidence intervals (i.e. the proportion of confi-
dence intervals that contain the true predictor value) were
evaluated.
Results: We found that RMSE was lowest when adopting JMI or
CMI, although imputation of individual predictors did not always
lead to substantial accuracy improvements with regards to the
RMSE, as compared to mean imputation. JMI and CMI appeared
particularly useful when the values of multiple predictors of the
model were missing. Coverage reached the nominal level (i.e.
95%) for both CMI and JMI.
Conclusions: Multiple imputation using, either CMI or JMI, is recom-
mended when dealing with missing predictor values in real time
settings.
Keywords: Missing data, multiple imputation, real-time imputation,
prediction, decision support system, electronic health care records
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Background: Mortality from chronic liver disease (CLD) is rising. This
is despite ‘early warning’ from commonly requested liver function
tests (LFTs) which are abnormal in around 20% of cases, providing a
clear opportunity for earlier diagnosis and intervention. Intelligent
liver function testing (iLFT) is a revolutionary system which aims to
increase early diagnosis of CLD. The referring clinician provides infor-
mation on alcohol intake and co-morbidities, allowing an automated
algorithm to reflex relevant tests without further venepuncture when
initial LFTs are abnormal. Recommended outcomes are then pro-
vided: secondary care referral; primary care follow-up; or further in-
vestigations and referral criteria. This replaces the current, protracted
system in which tests are often repeated over many years before
diagnosing irreversible liver cirrhosis. iLFT is cost-effective and pro-
vides a window of opportunity for lifestyle modification and
treatment.
We aimed to improve healthcare by identifying an appropriate care
pathway for individual patients, utilise the existing potential of
equipment and working practices, and improve service access to
Hepatology, ensuring appropriate patients are seen by specialists.
Methods: A retrospective analysis was performed of iLFT requests
and results in the first year, and a user questionnaire was analysed.
Results: 2362 iLFT requests were received over 12 months, identify-
ing 509 patients with advanced CLD requiring secondary care review,
and 1504 patients with early CLD in whom lifestyle modifications
could prevent disease progression. The proportion of liver testing
made up by iLFT increased month-on-month; iLFT now accounts for
3% of monthly LFTs. 98 of 100 local General Practitioners surveyed
would recommend iLFT to colleagues.
Conclusions: iLFT is a successful system which utilises currently avail-
able resources to increase the diagnosis of CLD and provide appro-
priate referral advice. This creates a means to manage the growing
healthcare burden from CLD and allows access to specialist care for
appropriate patients.
Keywords: Liver, algorithm, cirrhosis, fibrosis, primary care,
diagnosis
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Background: There is no standardized terminology for describing
diagnostic test accuracy (DTA) studies, which presents a barrier to
clear and informative reporting of primary studies and hinders efforts
towards making valid evidence synthesis. In a previous project, we
observed a heterogeneous and sometimes confusing use of termin-
ology for describing DTA study design features in reviews prepared
for NICE guidelines[1].
We aimed to develop a coherent set of terms for describing DTA
study design features.
Methods: Based on data from our previous study, and newly col-
lected data on features and terms, we are performing an iterative
clarification, sorting, and categorization of all the terms and features
we identified. These will be integrated in a coherent and complete
set of terms, as a prototype. The strengths and limitations of this
prototype are evaluated through an electronic survey. Participants
are experienced DTA researchers and non-academic stakeholders
and include health technology assessment groups, DTA guideline de-
velopers, and collaborators from industry. The survey responses are
used to adapt and modify the set of terms. In the last phase, the set
of terms will be piloted among end users with varying levels of DTA
experience, to evaluate if it facilitates informative descriptions of DTA
study designs.
Results: Our set of terms, developed with the input from a large
group of experts and stakeholders, can be used to describe a DTA
study in sufficient detail, without ambiguity.
Conclusion: We believe that having a standardized and agreed upon
set of terms can reduce the use of misleading, subjective, ambiguous
and heterogeneous wording when describing DTA research. This will
eventually enable secondary researchers and health care decision-
makers to better assess the validity and generalizability of DTA
evidence.
Keywords: Diagnostic test accuracy, study designs, terminology,
labelling
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Background: Microbiological tests requested from primary care are
currently almost entirely performed in a central NHS laboratory. New
diagnostic technologies allowing results to be available at the point
of prescription could contribute to antimicrobial stewardship.
We aimed to quantify the demand for microbiology tests in primary
care and highlight the most important individual and combinations
of tests, and pathogens to inform the development of new single
and multiplexed point-of-care tests.
Methods: A retrospective cohort of all Oxfordshire primary care pa-
tients for whom a microbiology test was requested between 2008-
2018. We described test frequencies overall, positive test results,
pathogens identified, and trends over time. We also investigated pat-
terns of co-testing in the same and subsequent visits with heat-maps
and hierarchical cluster analysis overall and in sex and age
categories.
Results: 1,596,752 microbiology tests were requested for 393,905 pa-
tients of which 65.3% were women and 48.8% aged 18-49 years old.
We organized individual tests into 19 microbiology test groups, 8
combined cultures and microscopies, and 11 related to individual
pathogens. Urine cultures and microscopies (n=673,612) accounted
for 42% of all microbiology tests and were mainly requested in isola-
tion but also in follow-up visits after 7 and 14 days. Of all urine cul-
tures, 27 % were positive and 26% had equivocal results. E. coli was
the most prevalent pathogen in urine cultures (65.2%). Antenatal
urine cultures and blood tests (Hepatitis B, HIV, Syphilis, and Rubella)
formed the most common combination of tests particularly among
women aged 18-49.
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Conclusions: The greatest burden of microbiology testing in primary
care can be attributable to urine cultures. Antenatal urine and blood
tests done in women aged 18-49 are also a significant contributor to
the burden of microbiology testing. Further research should focus on
the impact of the development of point-of-care tests on these care
pathways.
Keywords: Microbiology, primary care, testing
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Background: Public and patient involvement (PPI) in medical re-
search is defined as research carried out “with” or “by” members of
the public rather than “to,” “about” or “for” them [1]. PPI is a key part
of medical research, with many national health and funding organi-
sations stating PPI is essential including bodies from the UK,
Netherlands, America, Canada and USA [2]. There is little information
on how to integrate PPI into methodological research and the stake-
holders that should be considered as public contributors.
We aimed to provide information for PPI involvement in methodo-
logical research, including available resources and present a case study.
Methods: As a case study, we describe a methodological research
fellowship focusing on methods for determining the performance of
diagnostic imaging tests by including information on interobserver
variability and time to diagnosis. Within this project, we consulted
with colleagues with experience integrating PPI into their methodo-
logical research, PPI leads from local hospitals and research centres,
presented the research proposal to a PPI group for feedback and de-
veloped an integrated PPI approach.
Results: A description of the integrated PPI involvement for a meth-
odological research fellowship and list of resources available for guid-
ance. Some of the online resources include the INVOLVE National
Standards for Public Involvement and cost calculator [3.4]. Other re-
sources include links to toolkits and useful papers on public
involvement.
Conclusions: Investigators should plan PPI involvement in advance,
research available help in local area including colleagues, PPI leads,
and online support.
Keywords: PPI, methodological, research
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Background: The Observational Health Data Sciences and Informatics
(OHDSI) collaborative has established an international network of da-
tabases mapped to the Observational Medical Outcomes Partnership
(OMOP) Common Data Model [1], enabling large-scale analyses.
We aimed to develop of a framework for risk-based assessment of
heterogeneity of treatment effect (HTE) within the OHDSI setting of
analysis of observational data.
Methods: The steps required for the standardized analysis are: 1) defin-
ition of the problem, i.e. the treatment, the comparator and the out-
come(s) of interest; 2) identification of the database(s) in which the
framework will be applied; 3) development of the prediction model for
the outcome(s) of interest from a propensity score matched sub-
population of merged treatment and comparator cohorts, using a large
set of standardized predictor variables including demographics, condi-
tions, drugs, measurements procedures and observation concepts; 4)
estimation of the propensity scores within strata of predicted risk using
large-scale regularized regression, selecting from the same large set of
candidate variables; 5) estimation of relative and absolute treatment ef-
fects within risk strata—matching or stratification on the propensity
score or inverse probability of treatment weighting can be applied.
Results: We compared angiotensin-converting enzyme (ACE) inhibi-
tors (treatment) to beta blockers (comparator) with regard to a set of
9 outcomes in patients with hypertension across three observational
databases.
Conclusions: Reproducible risk-based assessment of HTE in observa-
tional data is made possible. (Figure 1) The standardized nature of
the process allows its implementation at scale, while the common
data model enables collaboration across multiple sites with access to
different databases.
Keywords: heterogeneity of treatment effect, prediction, observa-
tional data, framework, electronic health records
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Background: Sporadic Creutzfeldt-Jakob disease (sCJD) is the world's
most common invariably fatal human prion disease with an inci-
dence rate of 1–2 cases per million and year. Disease duration aver-
ages 5–6 months from diagnosis to death, but ranges from weeks to
several years.
We aimed to develop an individual prognostic prediction model
based on cerebrospinal fluid (CSF) biomarkers and other proposed
disease survival modifiers, which are easily obtainable in routine set-
tings at the time of diagnosis.
Methods: Probable or definite sCJD cases from a German surveillance
study (1993–2017) were included. The prognostic accuracy to predict
overall survival after sCJD diagnosis was measured by the c statistic
of a model derived from a multivariable Cox proportional hazard
regression.
Results: Complete information about age, sex, codon 129 genotype,
presence of 14-3-3 in the CSF, and CSF tau concentrations was avail-
able for 1,226 out of 2,908 sCJD cases. The median age at diagnosis
was 66 years (range 19–89 years). The male-to-female ratio was 1:1.
A Cox proportional hazard model containing age, sex, genotype, CSF
tau and the interaction terms age × tau, sex × tau, and sex × geno-
type was selected as the model with the highest c statistic (0.686,
95% CI 0.665–0.707) using cross-validation. This model was well cali-
brated. A score chart was derived to predict 6-month survival and
median survival time (Figure 1).
Conclusions: We developed an individual prediction model with
moderate to good accuracy. The score chart developed in this study
serves as a hands-on prediction tool for clinical practice, allowing
better planning of care after sCJD diagnosis and easier identification
of potential participants for future treatment trials.
Keywords: Cerebrospinal fluid, neurodegeneration, prognosis, spor-
adic Creutzfeldt-Jakob disease, tau
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Background: The performance of risk prediction models is often
characterized in terms of discrimination and calibration. The Re-
ceiver Operating Characteristic (ROC) curve is widely used for
evaluating model discrimination. When comparing ROC curves be-
tween development and validation samples, the effect of case-
mix makes the interpretation of discrepancies difficult. Further,
compared to model discrimination, evaluating model calibration
has not received the same level of attention in medical literature.
The most commonly used graphical method for model calibra-
tion, the calibration plot, requires specification of smoothing pa-
rameters or number of groups.
Methods: This abstract introduces the ‘model-based’ ROC (mROC)
curve, the ROC curve that should be observed if the prediction
model is calibrated in the external population. Unlike the ROC curve,
the mROC curve is affected by even monotonical transformations of
predicted risks, thus is sensitive to model calibration. We show that
moderate calibration (actual risk being p% among those with pre-
dicted risk of p%) is a sufficient condition for the convergence of
mROC and ROC curves. Accordingly, we propose a novel test statistic
for calibration that does not require any arbitrary parameterization.
Results: Through an example, we demonstrate how mROC separates
the effect of case-mix and model mis-calibration when comparing
ROC curves from different samples (Figure 1). We present the results
of simulation studies that confirm the properties of the new calibra-
tion test. A case study puts the developments in a practical context.
Conclusion: mROC can easily be constructed and used to interpret
the effect of case-mix and calibration on the ROC plot. This can facili-
tate interpretation of the ROC curve in external validation studies.
Fig. 1 (abstract 63). Application in Truven MarketScan Commercial
Claims and Encounters (CCAE) database containing enrollees in US
employer-sponsored insurance health plans. Patients are divided into
quarters of predicted risk of hospitalization with heart failure.
Observed event rates by risk quarter are given (top). The hazard
ratios—estimated using stratification on the propensity score—show
a decreasing trend in favor of ACE inhibitors (middle). The benefits
of ACE inhibitors increase strongly at the absolute scale with
increasing hospitalization risk (bottom, absolute risk reduction
increases from 0.06% to 0.72%).
Fig. 1 (abstract 64). Score chart for predicting 6-month survival
probability of sCJD patients
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Given the popularity of ROC curves among applied investigators, this
framework can further promote assessment of model calibration.
Keywords: Clinical prediction, risk prediction, receiver operating char-
acteristic curve
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Background: Assessment of the incremental gain and impact of a
novel marker to better predict disease risk is an ongoing quest in
many clinical disciplines. For binary and time-to-event outcomes, two
popular metrics used to assess incremental gain are difference in the
C-index or the Area under the ROC curve (dAUC) and Integrated Dis-
crimination Improvement (IDI). However, inference for these two
measures are complex for their non-standard distributions, especially,
while comparing nested models that are build and evaluated on the
same dataset.
Methods and results: We propose an easy-to-implement permuta-
tion test for dAUC and IDI to provide exact inference for the incre-
mental gain. Via extensive simulation studies, we show that for small
to moderate sample sizes, the type I error rate and power for dAUC
and IDI are comparable the type I error rate and power for the likeli-
hood ratio test and Wald test for comparing nested logistic and Cox
proportional hazards models. In addition, we also assess the perform-
ance of the permutation test for classification trees. We demonstrate
the approach in a real dataset where the incremental value of time-
to-first cigarette to select ever-smokers for lung cancer was assessed.
Conclusions: We show that permutation test can be used effectively
for assessing incremental value of a marker based on nested models.
Our work provides an viable solution for assessment of incremental
gain for many scientific and clinical scenarios.
Keywords: Incremental value, AUC, IDI, permutation test, logistic re-
gression, Cox proportional hazards model
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Background: Putting data together from different sources into a
homogeneous data resource would enable unprecedented opportun-
ities to study human health. However, these disparate collections of
data are inevitably heterogeneous and have made aggregation a dif-
ficult challenge. We focus on the issue of content heterogeneity in
data integration. Traditional approaches for resolving content hetero-
geneity map all source datasets to a common data model that in-
cludes only shared data items.
Our focus is on integration of structured data. We assume that each
one of these datasets that needed to be integrated consists of a sin-
gle table; and that each of these datasets describes a disjoint set of
entities. Therefore, record linkage is not needed.
Methods: We propose the development of improved, probabilistic
approaches for data integration, capable of advancing the timely util-
isation of large-scale biomedical data resources. Our approaches aim
to forego the need for perfect data standardisation by employing a
probabilistic post-alignment of data items that is integrated with
statistical inference. Using these approaches, missing or semantically
ambiguous information is estimated from datasets potentially rele-
vant for answering the research question.
Results: The MAximizing Sle ThERapeutic PotentiaL by Application of
Novel Stratified approaches programme (MASTERPLANS) aims to im-
prove care for Systemic Lupus Erythematosus patients by taking a
precision medicine approach to identifying groups of patients that
respond to biologic therapies. Based on dataset examples provided
by MASTERPLANS we describe and evaluate the proposed probabilis-
tic data integration approaches.
Conclusions: Our approaches insist on the future existence of health
data heterogeneity. They strive for post alignment of Big datasets. As
a post-alignment of heterogeneous data sources will be always im-
perfect and it is not a problem if we estimate the probability that
they are. Our approaches are also pragmatic because they always
provide an answer.
Keywords: Big Data, probabilistic data integration, data heterogeneity
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Background: Increased resources have been spent on cancer bio-
marker (BM) discovery, for both prognostic and diagnostic purposes,
but very few of these BMs have been clinically adopted. Therefore, in
an attempt to bridge the gap between BM discovery and clinical use,
this study aims to generate a BM assesment toolkit based on literature-
reported attributes associated with successful BM implementation.
Methods: A checklist of BM attributes was created using Medline
and Embase databases according to PRISMA guidelines. Retrospect-
ive validation of the checklist was achieved by six independent sys-
tematic literature searches using keywords/subheadings related to
successfully implemented (n=2) and stalled (n=5) breast cancer BMs.
Composite aggregated scores were generated for each selected
Fig. 1 (abstract 65). Empirical ROC in the development (blue) and
validation (black) samples, and mROC (red) curves for an exemplary
study.
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publication based on the presence/absence of a characteristic listed
in the BM checklist. Subsequently, logistic regression was performed
to assess the relationship of each BM attribute/total average scores
and the clinical implementation status.
Results: Attributes retrieved from literature and guidelines (n=125)
were included in the BM toolkit. Average total % scores generated
based on these attributes were significantly higher in the successfully
implemented BM group (P<0.0001). The logistic regression model be-
tween the average total % score and BM clinical implementation sta-
tus reached significance with sensitivity and specificity of 97.5% and
95.4%, respectively.
Conclusions: This study generated a validated checklist with
literature-reported attributes linked with successful BM implementa-
tion. Upon future work and prospective validation, this toolkit could
be used i) to detect BMs with the highest potential of being clinically
implemented and ii) to shape how BM studies are designed and
performed.
Keywords: Biomarkers, clinical implementation, checklist
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Background: Many factors can introduce bias and imprecision (i.e.
measurement uncertainty) into in-vitro test measurements. If, as a re-
sult, test values are incorrectly observed as lying outside of key deci-
sion thresholds, then this uncertainty can affect clinical and health-
economic outcomes. Currently, however, this impact is rarely consid-
ered within laboratory or test evaluation studies.
We aimed to illustrate methods for assessing the impact of test
measurement uncertainty on outcomes.
Methods: In a recent review, we identified methods for assessing the
impact of measurement uncertainty on test outcomes. In this study,
we applied the error model simulation approach (based on iterative
application of bias and imprecision) to a case study test: faecal cal-
protectin (FC) for the diagnosis of Inflammatory Bowel Disease (IBD).
Two primary care FC pathways were evaluated: the 'NICE FC path-
way' (single FC test; 50 μg/g diagnostic cut-off threshold) and the
'York FC Care Pathway (YFCCP)' (a repeat-FC strategy; 100 μg/g
threshold). The error model simulation was embedded within an
existing decision analytic model, to evaluate the impact of measure-
ment uncertainty on diagnostic accuracy, clinical-utility and cost-
effectiveness outcomes.
Results: The NICE FC pathway was found to be highly volatile to
positive bias. The YFCCP meanwhile was largely robust to increased
measurement uncertainty, suggesting that this pathway is suitable
for wide-scale adoption. Using the simulated results, acceptable re-
gions of analytical performance (i.e. maximum bounds for bias and
imprecision) were identified, based on the impact of measurement
uncertainty on clinical and health-economic outcomes.
Conclusions: The error model approach provides a useful method for
assessing the impact of measurement uncertainty on outcomes. This
information is important both for clinical decision makers (to inform
whether or not to adopt a new test) and laboratory professionals (to
inform evidence-based implementation and monitoring practices for
tests within the laboratory).
Keywords: Measurement uncertainty, simulation, test evaluation
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Background: For medical tests that have a central role in clinical decision-
making, international laboratory guidelines advocate outcome-based analyt-
ical performance specifications (APS) – i.e. measurement performance goals
derived from the expected impact of measurement uncertainty on clinical
outcomes. The identification of outcome-based APS relies on indirect stud-
ies (e.g. simulation) to assess the impact of test measurement uncertainty
on outcomes. Currently however, there is limited awareness of available
methods in this context. Increased awareness and understanding of indirect
study methods could further inform test evaluation methodologies.
We aimed to identify indirect methods for assessing the impact of
measurement uncertainty (i.e. bias and imprecision) on outcomes
(clinical performance, clinical utility and/or costs).
Methods: A methodology review consisting of database searches and ex-
tensive citation tracking was conducted to identify studies using indirect
methods to incorporate or evaluate the impact of test measurement uncer-
tainty on outcomes.
Results: Eighty-two studies were identified, most of which evaluated the
impact of imprecision and/or bias on clinical accuracy. A common three-
step analytical framework underpinning the various methods was apparent:
(1) estimation of “true” test values; (2) estimation of measured test values
(incorporating uncertainty); and (3) estimation of the impact of discrepan-
cies between (1) and (2) on specified outcomes. Simulation techniques
have become a common approach over the past two decades; the most
flexible method – the error model simulation approach – is based on the it-
erative application of bias and imprecision onto baseline “true” values.
Whilst previous studies have focused on clinical performance (e.g. diagnos-
tic accuracy), evaluations can be feasibly extended to clinical-utility and
cost-effectiveness outcomes using decision analytic models.
Conclusions: Various approaches are available for conducting indir-
ect assessments to inform outcome-based APS and test evaluations.
This study provides a useful overview of methods and key consider-
ations for future research.
Keywords: Measurement uncertainty, methodology review, analytical
performance specifications, test evaluation
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Background: Obstetric healthcare relies on an adequate antepartum
risk selection. Most guidelines used for risk stratification, however, do
not assess absolute risks. In 2017, a prediction tool was implemented
in a Dutch region. This tool combines first trimester prediction
models with obstetric care paths tailored to the individual risk profile,
enabling risk-based care (RBC).
We aimed to assess impact and cost-effectiveness of RBC compared
to care-as-usual (CAU) in a general population.
Methods: A before-after study was conducted using two multicenter
prospective cohorts. The first cohort (2013-2015) received CAU, the
second cohort (2017-2018) received RBC. Health outcomes were 1) a
composite of adverse perinatal outcomes and 2) maternal quality ad-
justed life years (QALYs). Costs were estimated using a healthcare
perspective from conception to six weeks after the due date. Mean
costs per woman, cost differences between the two groups, as well
as incremental cost effectiveness ratios were calculated. Sensitivity
analyses were performed to evaluate the robustness of the findings.
Results: In total 3,425 women were included. (Figure 1) In nulliparous
women there was a significant reduction of perinatal adverse out-
comes among the RBC group (aOR 0.56; 95%CI 0.32-0.94), but not in
multiparous women. Mean costs per pregnant woman were signifi-
cantly lower for RBC (mean difference -€2,766, 95%CI -€3,700 –
-€1,825). No differences in maternal quality of life, adjusted for base-
line health, were observed.
Conclusion: In the Netherlands, RBC in nulliparous women was asso-
ciated with improved perinatal outcomes as compared to CAU. Fur-
thermore, RBC was cost-effective compared to CAU and resulted in
lower healthcare costs.
Keywords: Impact study, prediction models, obstetrics, risk-based care,
perinatal outcomes, cost-effectiveness, Expect study
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Background: Pre-eclampsia is the most predicted obstetric outcome,
with more than 130 prognostic models developed.[1] A quarter of
these have been externally validated, and showed only modest pre-
dictive performance, characterised by methodological shortcomings
in development including overfitting of models, small event numbers
in development datasets and predictors not varied enough to ad-
equately capture the differences between women. Access to IPD
from multiple studies will provide increased sample size with more
outcomes to evaluate several candidate prognostic factors, beyond
what would have been possible in a single study, to subsequently
develop clinically relevant and robust models. It will also enable the
evaluation of any prediction model developed across different set-
tings and population case-mix.
We aimed to develop and validate pre-eclampsia prediction models
using IPD from multiple studies.
Methods: Logistic regression with a random intercept to account for
clustering by study for model development. Internal-external cross-
validation using random-effects meta-analysis to summarise perform-
ance measures across studies.
Results: The International Prediction of Pregnancy Complications
(IPPIC) network[2] is a group of 125 researchers contributing data of
3,674,684 pregnancies from 78 datasets. Twelve prediction models
were developed, four each for any, early and late-onset pre-
eclampsia. 3-11 datasets were used to develop each model depend-
ing on the availability of predictors within datasets. Average models
discrimination were good (0.68-0.83), however calibration perform-
ance was heterogeneous across datasets. The models showed the
highest net-benefit for predicted probability thresholds in nulliparous
women at thresholds above 5%.
Conclusions: The IPPIC models on average showed promising pre-
dictive performance. However before application in practice, recali-
bration of model parameters to particular populations and settings
may be needed. Additional predictors may improve the predictive
performance of the models.
Keywords: Pre-eclampsia, prediction model, individual participant data
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Background: With about 70 published prognostic models, pre-
eclampsia is the most frequently predicted outcome in obstetrics, yet
only 10% have been externally validated,1 and none are recom-
mended in national guidelines for routine clinical use, partly due to a
paucity in external validation. Access to individual participant data
(IPD) from multiple studies allows for external validation in different
populations. It saves cost by reusing existing data thereby reducing
research waste, and increases the sample-size with more outcomes
beyond what would have been possible in a single study, allowing
for evaluation of prediction models of rare conditions, such as early-
onset pre-eclampsia, which affects only 0.5% of all pregnancies.
We aimed to assess the external predictive performance of existing
prognostic models for pre-eclampsia within the UK healthcare
setting.
Methods: Systematic review and external validation of prognostic
models using IPD meta-analysis. Performance was evaluated using
measures of discrimination, calibration and net-benefit. Random-
effects meta-analysis was used to summarise and estimate hetero-
geneity in model performance across studies.
Fig. 1 (abstract 71). flowchart of included women
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Results: IPD from 11 UK cohort studies (217,415 pregnant women)
within the International Prediction of Pregnancy Complications net-
work[2] were used for external validation. Medline and Pubmed
searches up to December 2017 identified 71 articles, describing the
development of 131 prognostic models for predicting pre-eclampsia.
Half (51%, 67/131) provided the full model equations required for
validation, but only a third (36%, 24/67) could be validated because
all predictors in the model were recorded in at least one study of the
IPD. Summary C-statistics were modest (0.6-0.7) and calibration was
generally poor (<1) suggesting overfitting.
Conclusions: Evidence is limited to support the implementation of
evaluated models in clinical practice. Findings suggests methodo-
logical failings in their development.
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Background: Sample size requirements for external validation of a pre-
diction model are often based on ‘rules-of-thumb’ such as requiring at
least 100 (or even 200) events or non-events. Although often over-
looked, it is not simply the point estimates of performance measures
that are of interest but also the precision in these estimates. Re-
searchers should therefore ensure that validation studies are large
enough to estimate performance measures with reasonable precision.
We aimed to investigate factors affecting precision of performance
measures, and demonstrate a simulation-based approach for deter-
mining appropriate sample sizes for external validation studies.
Methods: We conducted a simulation study to investigate the rela-
tionship between various factors (outcome prevalence, linear pre-
dictor distribution (LPSD), total sample size) and precision of
performance measures for a logistic regression model, and devel-
oped a simulation-based approach to determine the minimum sam-
ple size required to achieve sufficiently narrow confidence intervals
for all predictive performance measures of interest.
Results: The simulation study demonstrates that factors other than
number of events affect precision of performance measures (includ-
ing LPSD and total sample size) and that even with 100 or 200
events and non-events, 95% CIs remain wide in some settings. By
specifying the desired precision of performance measures and distri-
bution of the linear predictor (e.g. based on development data), our
simulation-based approach can be used to tailor sample size calcula-
tions. The approach will be illustrated for designing a validation
study for a diagnostic model for deep vein thrombosis, based on
published data.
Conclusions: Sample size for validation of logistic models cannot be
solved easily using closed form solutions and rules-of-thumb are
often too simplistic and fail in individual settings. In situations where
the distribution of the linear predictor can be ascertained, a
simulation-based approach allows the sample size to be tailored to
the setting.
Keywords: Sample size, validation, prediction, simulation
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Background: Guidelines exist for reporting the development and val-
idation of prediction models (TRIPOD), and for reporting systematic
reviews (PRISMA). However, no specific guidance exists for reporting
systematic reviews of prediction models which can have different
aims, ranging from identifying models through to comparing predict-
ive performance of models. Therefore, existing reporting guidelines
require modification to be more suitable for systematic reviews of
prediction model studies.
We aimed to develop an extension to TRIPOD, specific to systematic
reviews of prediction model studies.
Methods: Existing reporting guidelines were reviewed. Relevant
guideline items were combined and assessed for suitability by two
researchers, considering the different aims of systematic reviews: i)
identification of prediction models within a broad clinical field, ii)
identification of prediction models for a target population, iii) identi-
fication of models for a particular outcome, iv) assessing the perform-
ance of a particular model, and v) comparison of models (in terms of
predictive performance). Item suitability and wording were discussed
within the working group and a draft extension to TRIPOD was pro-
duced. An online Delphi survey was conducted, using researchers
with experience in systematic review and prediction modelling to
provide feedback on the proposed items.
Results: PRISMA and TRIPOD-Cluster (in development) were identi-
fied as the most relevant reporting guidelines. They contained many
overlapping items; while PRISMA contained some items specific to
systematic reviews, TRIPOD-IPD contained some items specific to pre-
diction models. Items from both guidelines were combined, resulting
in many items being merged and modified, while other items spe-
cific to model development or individual participant data were re-
moved. Feedback from the Delphi survey was incorporated and the
draft extension will be presented, welcoming feedback before a sec-
ond Delphi survey.
Conclusions: TRIPOD-SR is an extension of existing reporting guide-
lines that is being developed to provide more tailored guidance for
reporting systematic reviews of prediction models.
Keywords: Reporting guidelines, systematic reviews, prediction
models
76.
Use and misuse of the calibration slope
Richard Stevens1, Katrina Poppe2
1Nuffield Dept Primary Care Health Sciences, University of Oxford,
Woodstock Road, Oxford, United Kingdom; 2Faculty of Medical and
Health Sciences, University of Auckland, Auckland, New Zealand
Correspondence: Richard Stevens
Diagnostic and Prognostic Research 2021, 5(Suppl 1):76.
Background: The slope of a calibration plot is often referred to as
“calibration slope”. Methodology texts emphasize the slope should
not be used in isolation but accompanied by other metrics and
graphs: poor calibration, by any definition, can occur even when the
slope is perfect (equals 1).
Method: We review recent usage of the calibration slope.
Results: In 33 validation papers (24 external) published 2017-2018,
25 papers identified the slope with calibration, 1 identified calibra-
tion slope with discrimination and 7 used the term calibration slope
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without explicitly interpreting it. In 17 papers (52%) the slope was
used as sole measure of calibration. We are currently reviewing pa-
pers from 2019 and 2020.
Conclusions: The paper often cited as the origin of the “calibration
slope” did not use the term calibration, but “spread”. More recently
“spread” has been identified in some papers as an aspect of calibra-
tion and in others as an aspect of discrimination, sometimes by the
same authors. We resolve this apparent paradox by proposing that
calibration and discrimination are not a dichotomy. If we equate the
A (calibration-in-the-large), B (calibration slope) and C (discrimination)
of Steyerberg and Vergouwe’s ABCD[1] with bias, spread and order-
ing, then we can see that good calibration-in-the-large equates to
low bias; calibration as often defined equates to low bias and ad-
equate spread; good discrimination requires correct spread and cor-
rect ordering; and moderate to strong calibration, as defined by Van
Calster[2], requires low bias, adequate spread and correct ordering.
Authors, reviewers and editors have a duty to discourage the percep-
tion that calibration is a unidimensional construct quantifiable by a
single statistic, the slope.
Keywords: Validation, calibration, discrimination, spread, slope
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Background: Analysis using random effects linear models is the
established method used in biological variability studies to attribute
the observed variability arising from between-patient differences,
within-patient differences, and measurement error. However, these
models assume underlying normality, and thus may not be applic-
able for biomarkers based on counts.
We aimed to present methods for estimating sources of variability in
count-based biomarkers and apply and compare approaches in a
case study of patients with Sjogren’s syndrome.
Methods: Both Poisson and negative binomial models are appropri-
ate for analysis of count data, and methods for obtaining between
and within-patient variance estimates are described in Leckie et al[1].
We analysed the biomarker data using random effects Poisson and
negative binomial models, and for comparison, using a random ef-
fects linear regression model. The intra-class-correlation (ICC) was cal-
culated as a ratio of the between-patient variance over the total
variance, and was compared across the different models. The AIC
and BIC criteria were used to assess each model’s performance. Data
from 32 patients with Sjogren’s syndrome was used as a case study,
considering the focus score, calculated for each salivary gland ob-
served in each biopsy as the number of foci over the glandular area,
multiplied by 4. Between-patient and within-patient-between-gland
sources of variability were estimated.
Results: The ICC estimates obtained from Poisson (0.323) and nega-
tive binomial models (0.310) were similar, and higher than the linear
regression model (0.222). AIC and BIC values were similar for Poisson
(AIC=463.63, BIC=469.84) and negative binomial models (AIC=465.55,
BIC=474.87) and indicated both were a better fit than the linear re-
gression model (AIC=632.69, BIC=642.01).
Conclusions: It is important to properly model the distribution of
biomarkers based on count data to correctly estimate sources of vari-
ability and measurement error.
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Background: Biomarkers and tests are often used to diagnose or
monitor a condition, or function as outcomes in clinical trials. Key
questions arises on the measurement properties of biomarkers when
used for such purposes, as measurements are subject to variability,
such as analytical, biological, and intra/inter-rater. Methods for meta-
analysis are required in order to synthesize results in systematic re-
views from individual studies assessing the reliability of biomarkers
or tests.
We aimed to review the current state of methods used for meta-
analysis of reliability estimates reported in biological variability
studies.
Methods: Published systematic reviews reporting the reliability of
any test measuring presence or progress of any pathological condi-
tion were identified by searches of Medline and Embase from 2010-
19. Detailed information was extracted regarding: the experimental
test; the condition; the review methodology including the literature
search, approach to quality assessment, the statistical methodology
used to examine reliability; and the results each study reported.
Results: 228 reviews were identified, with only 23 performing a
meta-analysis of the reported estimates. The most common meta-
analytical estimate was the intra class correlation (61%), with 3 stud-
ies using the Fisher’s Z transformation to account for the non-normal
distribution of ICC data. Other reported statistics include the Kappa
coefficient, standard error of measurement, coefficient of variation,
limits of agreement, repeatability coefficients, linear regression based
R2, and correlation coefficients. The majority of studies (78%) con-
structed forest plots and used random effects models to account for
differences between studies. One study used a fixed effects model,
while the method was not specified in 2 studies. Other approaches
include pooling the data and performing linear regression, Bland-
Altman analysis on the test-retest values, and describing the distribu-
tion of the study results.
Conclusions: Any limitations in the statistical estimates and meta-
analysis methods used to date will be explored and presented.
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Background: Point of care blood testing to aid diagnosis is becoming
increasingly common in acute ambulatory settings and enables
timely investigation of a range of diagnostic markers. However, this
testing allows scope for errors in the pre-analytical phase, which
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depends on the operator handling and transferring specimens cor-
rectly. The extent and nature of these pre-analytical errors in clinical
settings has not been widely reported.
Methods: We carried out a convergent parallel mixed-methods ser-
vice evaluation to investigate pre-analytical errors leading to a ma-
chine error reports in a large acute hospital trust in the UK. The
quantitative component comprised a retrospective analysis of all re-
corded error codes from Abbott Point of Care i-STAT 1, i-STAT Alinity
and Abbott Rapid Diagnostics Afinion devices to summarise the error
frequencies and reasons for error, focusing on those attributable to
the operator. The qualitative component included a prospective
ethnographic study and a secondary analysis of an existing ethno-
graphic dataset, based in hospital-based ambulatory care and com-
munity ambulatory care respectively.
Results: The i-STAT had the highest usage (113,266 tests, January
2016-December 2018). As a percentage of all tests attempted, its
device-recorded overall error rate was 6.8% (95% confidence interval
6.6% to 6.9%), and in the period when reliable data could be ob-
tained, the operator-attributable error rate was 2.3% (2.2% to 2.4%).
Staff identified that the most difficult step was the filling of car-
tridges, but that this could be improved through practice, with a per-
ception that cartridge wastage through errors was rare.
Conclusions: In the observed settings, the rate of errors attributable
to operators of the primary point of care device was less than 1 in
40. In some cases, errors may lead to a small increase in resource use
or time required so adequate staff training is necessary to prevent
adverse impact on patient care.
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Background: Familial hypercholesterolaemia (FH) is a common, life-
threatening genetic condition associated with long-term elevation of
cholesterol levels in the blood. A diagnosis of FH can be confirmed
by genetic testing; however, it is expensive, and can often be mistar-
geted due to limitations of the scoring systems used to refer
patients.
We aimed to develop a model using clinical data to improve the tar-
geting of genetic testing by predicting the likelihood of a patient
having a variant causing FH.
Methods: Data were obtained from 243 patients referred for genetic
testing on suspicion of having FH. Forward stepwise logistic regres-
sion was performed, with variant status (binary) as the dependent
variable, and age, sex, individual components of the Dutch Lipid
Clinic Network (DLCN) criteria, total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), triglycerides, and low-density lipopro-
tein cholesterol (LDL-C) as independent variables. Variables were
added to the model until their inclusion was not significant (p>0.05),
and the Bayesian information criterion (BIC) increased. Backward
stepwise logistic regression was performed to verify the results and
ensure consistency. Receiver operating characteristic (ROC) curve
analysis and cross validation (CV) were performed.
Results: Data for 170 patients remained after exclusion of missing
data and outliers. The optimal model contained the variables age,
LDL-C, and triglycerides. The regression equation for this model was:
Probability of FH causing variant = (0.74768 x LDL-C) – (0.06656 x
age) – (1.26284 x triglycerides) – 0.06555. The area under the ROC
curve (AUROC) for the model was 0.82, with an R2 of 0.25 and test
error rate following CV of 0.25.
Conclusions: The model displayed promising results, and shows po-
tential for improving the targeting of genetic testing in patients sus-
pected of having FH. Interestingly, no individual components of the
DLCN criteria were retained in the optimal model. Further work is re-
quired to develop and validate the model.
Keywords: Familial hypercholesterolaemia, genetic testing, variant,
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Background: Familial hypercholesterolaemia (FH) is associated with
the long-term elevation of cholesterol levels in the blood. According
to guidance from the National Institute for Health and Care Excel-
lence (NICE), FH is suspected if total cholesterol exceeds 7.5 and 9
mmol/L in people under and over 30 years of age, respectively. The
use of these cut-offs may over diagnose older people whose choles-
terol has risen due to lifestyle factors, and underdiagnose younger
people who have not reached the threshold, but may be at risk.
We aimed to develop an interactive application which places a pa-
tient on a specific population-based cholesterol centile according to
their age and sex to improve the identification of people at risk of
FH.
Methods: Health Survey for England (HSE) data were obtained from
NHS Digital covering seven years between 2003 and 2014. Data for
age, sex, high-density lipoprotein cholesterol (HDL-C), total choles-
terol (TC), and use of lipid-lowering drugs were extracted. Centiles
were derived at intervals of 0.1 between 0.5 and 99.5, for non-HDL
cholesterol (non-HDL-C) [non-HDL-C = TC – HDL-C] and TC, in pa-
tients not being treated with lipid-lowering drugs.
Results: An interactive application was developed using Shiny that
places a patient on a specific cholesterol centile based on their age
and sex. Figure 1 shows an example of a 35 (I) and 55 (II) year old
male with a TC of 9 mmol/L, which places the example patients on
the 98.7 and 96.9 centiles, respectively.
Conclusions: When used in conjunction with current methods, the
use of age and sex adjusted cholesterol centiles could help improve
the identification of patients with FH, and therefore refine the selec-
tion of index cases for targeted genetic testing.
Keywords: Familial hypercholesterolaemia, cholesterol, identification,
application.
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Background: A conceptually oriented pre-processing of a large num-
ber of potential prognostic factors may improve the development of
a prognostic model and hence may play an important role in this
process. However, it is unclear, whether this assumption holds and
which way of pre-processing is optimal.
This study investigated whether various forms of conceptually ori-
ented pre-processing or the preselection of established factors was
superior to using all factors as input.
Methods: We made use of an existing project which developed two
conceptually oriented subgroupings of low back-pain patients with-
out taking the outcome into account. Based on the prediction of six
outcome variables by seven statistical methods, this type of pre-
processing was compared with domain specific principal component
scores, medical experts’ preselection of established factors as well as
with using all 112 available baseline factors.
Results: Subgrouping of patients was associated with low prognostic
capacity. Applying a Lasso-based variable selection to all factors or to
domain-specific principal component scores performed best. The pre-
selection of established factors showed a good compromise between
model complexity and prognostic capacity.
Conclusions: The prognostic capacity is hard to improve by means of a
conceptually oriented pre-processing when compared to purely statis-
tical approaches. However, a careful selection of already established
factors combined in a simple linear model should be considered as one
option when constructing a new prognostic rule based on a large num-
ber of potential prognostic factors.
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Background: The results of a diagnostic accuracy are often two pa-
rameters which we have to interpret together: Sensitivity and specifi-
city, false positive and true negative rate, positive and negative
predictive value, test positive rate and sensitivity, change in false
positive and true negative rate, change in sensitivity and specificity,
etc. For the interpretation, we often assign weights or utilities to
each rate, and consider a weighted average. However, different
stakeholders may use different weights, and the weights may also
vary with the intended application of the test. This raises the ques-
tion how we should present the results of a diagnostic accuracy
study – and in particular their uncertainty – such that we can evalu-
ate different weights in a post hoc situation.
Methods: Post hoc analyses of weighted averages require testing null
hypotheses of the type that a weighted average is below a certain
threshold. This can be approached by comparing the corresponding
half space in the two-dimensional parameter space with a 95% confi-
dence region. However, this is a very conservative approach.
Results: We present as an alternative approach so-called comparison
regions, such that no overlap between the half space and the com-
parison region is equivalent to rejecting the null hypothesis at the
5% level.[1] This way we can test any hypothesis about any weighted
average, and in addition any hypothesis, which corresponds to the
complement of a convex sets. Figure 1 illustrates the point.
Conclusions: The results of a diagnostic accuracy study can be pre-
sented in a way, which allows post hoc testing of (linear) hypotheses
of weighted averages about two diagnostic accuracy parameters.
Keywords: Diagnostic accuracy studies, uncertainty, visualization,
sensitivity and specificity, false positive and true negative rate.
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Fig. 1 (abstract 81). Screenshots from the interactive Shiny
application (https://micncltools.shinyapps.io/miccentilesshinyapp/)
showing total cholesterol centile plots for a 35 (I) and 55 (II) year old
male with a total cholesterol of 9 mmol/L. The two example patients
are each indicated by a black dot on the plots.
Fig. 1 (abstract 83). The results of a single arm diagnostic accuracy
study visualized by the point estimate and a comparison region.
Four different hypotheses are tested post hoc. H0a nad H0b can be
rejected. H0c and H0d cannot be rejected.
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Background: Evaluating the performance of a biomarker is chal-
lenging when different tests exist for measuring the same marker.
Along with other sources of heterogeneity in systematic reviews
of diagnostic test accuracy (DTA) studies, this can further influ-
ence and confound the results of meta-analysis.
We here propose a strategy to combine multiple tests to measure
the same marker in a single meta-analysis. We apply this strategy to
a meta-analysis of DTA studies of the Enhanced Liver Fibrosis (ELF)
test, used in non-alcoholic fatty liver disease patients.
Methods: Our systematic search in five databases identified ten
studies. Two different ELF tests were proposed, each using a dif-
ferent formula, expressed on a different scale. We initially con-
ducted two meta-analyses, accounting for the multiple thresholds
(diagmeta package in R). We then (1) evaluated, in a separate
study of 502 samples, the presence of a linear relationship be-
tween the results of the tests. We (2) used the regression equa-
tion to obtain harmonized test results and (3) performed a single
meta-analysis, combining the results from all nine studies.
Results: Eight studies used one formula (Siemens) and two used
another (Guha). The first meta-analysis of the eight studies re-
sulted in an “optimal” threshold (maximum Youden) of 9.30, for
a sensitivity of 0.75 (95%CI 0.59; 0.87) and a specificity of 0.81
(95%CI 0.68; 0.90). After checking the linearity (R2: 0.995) and
mapping the results on the same scale (Figure 1A), a meta-
analysis of all ten studies was possible. This resulted in an “op-
timal” threshold of 9.38 for a sensitivity of 0.72 (95%CI 0.70;
0.90) and a specificity of 0.79 (95%CI 0.66; 0.88) (Figure 1B).
Conclusions: Our three-step method allows the combination of
multiple tests of the same marker in a single meta-analysis, facili-
tating the interpretation of the accuracy of using specific
thresholds.
Keywords: Meta-analysis, accuracy studies, harmonization
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Background: The comprehensive Prediction model Risk Of Bias AS-
sessment Tool (PROBAST) [1] was developed for reviews of clinical
prediction models (CPMs).
We aimed to assess whether PROBAST can identify CPMs that per-
form poorly at external validation and to develop a short form that is
equally capable to identify poorly performing CPMs.
Methods: We evaluated risk of bias (ROB) using the PROBAST on 102
CPMs from the Tufts Predictive Analytics and Comparative Effective-
ness Registry, compared to a short form consisting of six of the 20
PROBAST items anticipated to best identify high ROB. We then ap-
plied the short form to all CPMs in the Registry with at least 1 valid-
ation (n=556). Primary outcome was the change in the area under
the receiver operating characteristic curve (dAUC, available for 1,147
validations) between the derivation and the validation cohorts in low
versus high ROB CPMs.
Results: The full PROBAST classified 98 of 102 CPMS as high ROB.
The short form identified 96 of these 98 as high ROB (98% sensitiv-
ity), with perfect specificity. Perfect agreement with the full PROBAST
could be achieved with re-review of only a small number of low ROB
CPMs. In the full CPM registry, 529 of 556 CPMs (95%) were classified
as high ROB, 20 (4%) low ROB, and 7 (1%) unclear ROB. The median
change in discrimination was significantly smaller in low ROB models
(dAUC -0.9%, IQR -6.2% to 4.2%) compared to high ROB models
(dAUC -12%, IQR -33% to 2.6%; p<0.001).
Conclusions: High ROB is pervasive among published CPMs. It is as-
sociated with poor performance at validation, supporting the applica-
tion of PROBAST or a shorter version in reviews of CPMs.
Keywords: Prediction models, risk of bias, evaluation
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Fig. 1 (abstract 85). (A) Scatter plot of the correlation between two
tests: Test 1: Siemens and Test 2: Guha. Using the regression formula
of : Guha results = 0.8854*(Siemens results) - 8.6498. (B) Multiple
thresholds sROC (mtsROC) curve based on the multiple thresholds
model using homogenized thresholds. Circles represent information
on sensitivity and specificity.
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Background: The diagnosis of a clinical condition is usually the first
and more crucial step before initiating treatment. Diagnostic tests are
routinely used for confirming or excluding a target condition. Although
most diagnostic test accuracy (DTA) studies have focused on assessing
a single index test, increasingly studies and systematic reviews are com-
paring the accuracy of multiple index tests to facilitate the selection of
the best performing test(s) for patient care. For example, HPV DNA,
HPV mRNA, and co-testing (Pap test + HPV DNA or mRNA test) can be
used for cervical cancer diagnosis. But which test is the best? Since
studies that directly compare test accuracy are not always available and
comparisons between multiple tests constitute a network, DTA network
meta-analysis (DTA-NMA) has been proposed.
We aimed to identify and assess DTA-NMA methods for comparing
the accuracy of multiple diagnostic tests.
Methods: We conducted a methodological review of statistical and
empirical studies that performed, described, or evaluated a DTA-NMA
of at least 3 diagnostic tests. We searched PubMed, JSTOR, and Web
of Science. Studies of any design published in English were eligible
for inclusion. We also included relevant unpublished material.
Results: We included 38 relevant studies. The results will be pre-
sented at the Symposium. In particular, we will present the ap-
proaches that have been proposed together with a critique of their
strengths and limitations. In addition, using cervical cancer as a case
study, we will present an application of DTA-NMA methods to deter-
mine the most promising test (in terms of sensitivity and specificity)
for use as the primary screening test for cervical cancer and to iden-
tify which women need referral for colposcopy.
Conclusions: Statistical approaches for comparative DTA meta-
analysis of multiple tests differ and may influence interpretation and
decision-making.
Keywords: Network meta-analysis, diagnostic test, accuracy, indirect
comparison
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Background: It is increasingly recognized that clinical prediction
models (CPMs) often do not perform as expected when they are
tested on new databases. Independent external validations of CPMs
are recommended but often not performed.
Here we conduct independent external validations of acute coronary
syndrome (ACS) CPMs.
Methods: A systematic review identified CPMs predicting outcomes
for patients with ACS. Independent external validations were per-
formed by evaluating model performance using individual patient
data from 5 large clinical trials. CPM performance with and without
various recalibration techniques was evaluated with a focus on CPM
discrimination (c-statistic, % relative change in c-statistic) as well as
calibration (Harrell’s Eavg, E90, net benefit).
Results: Of 276 ACS CPMs screened, 23 (8.3%) were compatible with
the trials and 28 clinically appropriate external validations were per-
formed. The median c statistic of the CPMs in the derivation cohorts
was 0.76 (IQR, 0.74-0.78). The median c-statistic in these external
validations was 0.70 (0.66-0.71) reflecting a 24% decrement in dis-
crimination. Most of this decrement was due to narrower case-mix in
the validation cohorts compared to derivation cohorts, as the median
model based c-statistic was 0.71 (0.67-0.75). The median calibration
slope in external validations was 0.82 (0.72- 0.95) and the median
Eavg (standardized by the outcome rate) was 0.4 (0.3-0.8). Decision
curve analysis indicates that most models had a high risk of causing
net harm when not recalibrated, particularly if the decision threshold
is not near the overall outcome rate. (Table 1)
Conclusion: For ACS CPMs, independent external validations gener-
ally demonstrate that discrimination is relatively preserved once case
mix is taken into account. Since calibration is often poor, applying
‘off-the-shelf’ CPMs often risks net harm unless models are
recalibrated.
Keywords: Acute Coronary Syndrome, clinical prediction models, ex-
ternal validation
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Background: Development of diagnostics is best driven by a compre-
hensive understanding of the clinical need and optimal role of the
device within a care pathway.
We aimed to identify the potential roles of new diagnostic tests to
inform future development objectives.
Methods: A survey was sent to UK NHS doctors and nurses who
were involved in the care of patients with suspected sepsis.
Table 1 (abstract 87). Effects of updating on net benefit. Threshold is
the decision threshold and is represented in relation to the outcome
prevalence. N is number of independent external validations. % Above
refers to net benefit above the default strategy, % neutral refers to net
benefit not different from the default strategy and % Below refers to net
benefit less than the default strategy (net harm).
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Questions focused on current care pathways in sepsis, current avail-
ability and utility of tests for infection and the unmet clinical needs
in this pathway.
Results: Responses were received from 265 individuals across 68
NHS Trusts. The strongest role for a point of care (POC) sepsis test
was as a ‘rule-out’ test which was favoured by doctors but not nurs-
ing staff, who preferred a ‘rule-in’ test. 67% of respondents indicated
that the major cause of delay in caring for suspected sepsis patients
was initial identification and flagging of deterioration. Existing blood
tests did not greatly increase the confidence of consultants diagnos-
ing sepsis. The majority of those surveyed felt there was a role for a
POC sepsis test as they felt it would be quicker.
Conclusions: There is a need for sepsis diagnostics which are quicker
and more specific than existing tests, to inform early identification
and management of sepsis patients. Development of sepsis diagnos-
tics should focus on solving these needs.
Keywords: Survey, development, diagnostic, care pathway, sepsis,
point of care
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